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ABSTRACT 
Allergic diseases are a major medical concern with increasing prevalence in the 
world. Inflammation is one of the hallmarks of allergic diseases. Long chain n-3 
polyunsaturated fatty acids (PUFAs) have been shown to inhibit allergic inflammation, 
but their direct effect on activation of the mast cell, a major effector cell in allergic 
inflammation, is poorly understood. We hypothesized that long chain n-3 PUFAs inhibit 
mast cell activation through alteration of the expression of some signaling molecules 
and modification of )F İ UHFHSWRU , )Fİ5,) association with lipid rafts, membrane 
microdomains containing high levels of cholesterol, sphingolipid, transmembrane 
proteins, acylated proteins, and glycosylphosphatidylinisotol (GPI)-anchored proteins. 
Bone marrow-derived mast cells (BMMC) were cultivated from C57BL/6 wild type 
(WT) and fat-1 transgenic mice which express fatty acid n-3 desaturase and produce 
endogenous n-3 PUFAs. Exogenously, long chain n-3 PUFAs were supplemented to 
BMMC and human mast cell line laboratory of allergic diseases 2 (LAD2) cells. Mast 
cell degranulation, lipid-derived mediator release, and cytokine/chemokine production 
were evaluated following cell activation through )Fİ5,. )Fİ5, expression and signal 
transduction was determined by flow cytometry and western blot analysis.  
GC-MS analysis showed increased long chain n-3 PUFAs levels in whole cell and 
lipid rafts of fat-1 BMMC, compared to WT, and in whole cell long chain n-3 
PUFA-treated BMMC. Fat-1 BMMC produced less tumor necrosis factor (TNF) and CC 
chemokine ligand 2 (CCL2), and cysteinyl leukotrienes (cys-LTs), and showed reduced 
degranulation compared to WT BMMC after cell stimulation with immunoglobulin E 
(IgE)/antigen. Long chain n-3 PUFA exogenous supplementation caused decreased 
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degranulation, cys-LT synthesis and cytokine/chemokine production in activated 
BMMC and LAD2 cells. Western blot analysis showed that the expression of Lyn and 
linker for activation of T cells (LAT) and phosphorylation of Lyn and spleen tyrosine 
kinase (Syk) and LAT was inhibited in fat-1 BMMC compared to WT. In both BMMC 
and LAD2 cells, long chain n-3 PUFAs did not alter FHOOVXUIDFHDQGZKROHFHOO)Fİ5, 
expression+RZHYHU)Fİ5, was excluded from lipid rafts by long chain n-3 PUFAs in 
resting mast cells. Furthermore, the shuttling RI)Fİ5,to rafts of activated mast cells 
was inhibited by long chain n-3 PUFAs. After lipid raft disruption by depleting 
cholesterol, mast cell degranulation, cys-LT release and cytokine/chemokine 
production were reduced in both WT and fat-1 BMMC. In addition, )Fİ5, and Lyn 
localization to lipid rafts were suppressed by MBCD treatment. This study clearly 
indicates that long chain n-3 PUFAs inhibit )Fİ5,-mediated signal transduction and 
mediator release from mast cells E\GLVUXSWLQJ)Fİ5,ORFDOL]DWLRQDQGSDUWLWLRQLQJWR
lipid rafts, and supressing the expression of Lyn and LAT. Cholesterol is required for the 
inhibitory effect of long chain n-3 PUFAs on mast cell activation.  
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1.1 Mast cells and their role in inflammation and disease 
1.1.1 A brief introduction of mast cells: properties, origin and types  
Mast cells are tissue residing cells found throughout the body, preferentially in 
tissues that have direct interaction with the outer environment, such as skin, airway and 
gastrointestinal tracts (Abraham and St John, 2010). It has been suggested that mast cells 
would be as large as a human spleen if gathered in a single organ (Sayed et al., 2008). 
Mast cells can be found in all vertebrates, and are believed to be ancient immune cells 
that are a part of the innate immune defense system (Silver and Curley, 2013). In their 
cytoplasm, mast cells contain many granules that are rich in histamine, heparin, neutral 
proteases, acid hydrolases, major basic protein, carboxypeptidases, and some preformed 
cytokines and growth factors (Palker et al., 2010). The granule contents differ in mast 
cells residing in different tissues (Miller and Pemberton, 2002). Mast cell granules stain 
positive with toluidine blue because the granules contain negatively charged 
heparin-proteoglycan-protease complexes (Kitamura, 1989). 
Mast cells originate from pluripotent hematopoietic stem cells in bone marrow 
(Kirshenbaum et al., 1991). Immature mast cells leave the bone marrow, enter 
circulation, and then complete their differentiation in the local environment of the 
peripheral tissues in which they reside (Kambe et al., 2004). Mature mast cells are not 
present in the circulation under physiological conditions (Kitamura and Fujita, 1989). 
Both murine and human mast cells require stem cell factor (SCF), the ligand for cluster 
of differentiation (CD)117/c-Kit, for survival and proliferation (Galli et al., 1995). 
Interleukin (IL)-3 is critical for the in vitro cultivation of murine mast cells from their 
bone marrow precursors (Lantz et al., 1998). Other cytokines and growth factors may 
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also contribute to the development of mast cells, including IL-4, IL-9, IL-10, 
transforming growth factor beta (TGF-ȕDQGQHUYHJURZWKIDFWRU1*)(Okayama and 
Kawakami, 2006). On their own, these factors do not have direct effects on mast cell 
survival, proliferation, and response to activator, but they act synergistically with SCF or 
IL-3. For example, IL-4 does not support mast cell survival by itself, but it enhances 
mature mast cell proliferation and mediator release together with SCF by facilitating 
activation of mitogen-activated protein kinase (MAPK) and Akt pathways (Feuser et al., 
2011). IL-4 also promotes mature mast cells to produce T helper 2 (Th2) cytokines such 
as IL-5 and IL-13, and reduce tumor necrosis factor (TNF) and IL-6 synthesis (Lorentz 
et al., 2000). Interestingly, IL-4 has different effects on immature mast cells. It was 
reported that IL-4 decreases mast cell numbers in peripheral blood CD34+ progenitor 
cultures (Kulka and Metcalfe, 2005).  
Two types of rodent mast cells, connective tissue-type mast cells (CTMC) and 
mucosal-type mast cells (MMC), were documented based on different morphological 
and histochemical characteristics, and tissue homing preference (Enerback, 1966a). 
CTMC and MMC have different proteoglycan content in granules. Heparin content is 
high in CTMC, but lacking in MMC. MMC granules contain chondroitin sulphates A 
and B, which are not present in CTMC. Chondroitin sulphate E was found in granules of 
both types of mast cells (Enerback, 1966c). After alcian blue/safranin staining sequence, 
granules of MMC stain blue with alcian blue and granules of CTMC stain red with 
safranin. MMC and CTMC also express different profiles of proteases and membrane 
molecules, so they have different responses to stimulators and have different functions 
(Enerback, 1966b). Two types of mast cells have also been discovered in human, those 
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containing tryptase (MCT) and those containing tryptase and chymase (MCTC). MCTC 
also contain cathepsin-G, and carboxypeptidase, and are found mainly in connective 
tissues, such as skin, submucosa of stomach and intestine, breast parenchyma, and 
lymph nodes. MCTC seem to be similar to CTMC in rodents. MCT lack the other neutral 
proteases seen in MCTC and are located predominantly in the mucosa of the respiratory 
and intestinal tracts. MCT are believed to correspond closely to rodent MMC (Irani and 
Schwartz, 1994). 
1.1.2 Mast cell activation and products 
Mast cells can be activated by many different types of stimuli, including allergens, 
complement, antimicrobial peptides, adenosine, neuropeptides and physical stimuli 
such as low temperature (Galli et al., 2005). The principle activation pathway is 
mediated by the high affinity immunoglobulin E (IgE) receptor, Fc İ receptor I ()Fİ5,). 
In the 1970s, IgE was found to induce the release of histamine from mast cells (Ishizaka 
and Ishizaka, 1978))Fİ5,ZDVGLVFRYHUHGODWer and completely cloned in 1989 (Blank et 
al., 1989))Fİ5,LVH[SUHVVHGRQPDVWFHOOVDVDWHWUDPHULFĮȕȖZKLFKPHGLDWHVPDVW
FHOO¶VLQWHUDFWLRQZLWK,J( (Paolini et al., 1991). The cross-linking of IgE-bound )Fİ5,
by bivalent or multivalent antigen results in the initiation of receptor signaling, 
subsequent signal transduction, and maVWFHOODFWLYDWLRQ)Fİ5,ZLOOEHdiscussed in more 
detail in section 1.2. After activation, generally three groups of mediators are gradually 
released from mast cells. First, preformed mediators in granules, such as histamine and 
heparin, are released in seconds in a process termed degranulation. The second group of 
mediators is lipid-derived mediators such as prostaglandins (PGs) and leukotrienes 
(LTs), which are released in minutes. The third group of mediators is cytokines, 
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chemokines and growth factors which are released after gene transcription (Table 1.1). 
Mast cells can also produce other molecules such as nitric oxide (NO), reactive oxygen 
species (ROS) and antimicrobial peptides (Kalesnikoff and Galli, 2008). The first two 
groups are responsible for acute-phase reactions in allergic diseases resulting in 
vasodilation and increased vascular permeability (Hofmann and Abraham, 2009). The 
late-phase reactions, such as tissue swelling, fibrin deposition and leukocyte 
accumulation, are more often attributed to cytokines and chemokines (Hofmann and 
Abraham, 2009). By releasing mediators, mast cells play an important role in both the 
innate and adaptive immune responses and are especially vital in IgE-mediated allergic 
inflammation (Stelekati et al., 2007).  
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Table 1.1. Mediators produced by activated mast cells 
Mediators  Species  References  
Preformed mediators    
Histamine  Human, mouse (McClain et al., 1983; Wang 
and Lau, 2007) 
Serotonin  Human, mouse (Kushnir-Sukhov et al., 2007; 
Ringvall et al., 2008) 
Heparin  Human, mouse (Craig et al., 1993; Lindstedt et 
al., 1992) 
Tryptase  Human, mouse (Schwartz, 1990; Valchanov 
and Proctor, 1999) 
Chymase   Human, mouse (Brown et al., 2003; Craig and 
Schwartz, 1989) 
Major basic protein  Human (Butterfield et al., 1990) 
Cathepsin  Human (Meier et al., 1985) 
Carboxypeptidase A  Human, mouse (Goldstein et al., 1989; Serafin 
et al., 1987) 
Lipid-derived mediators   
PGD2 Human, mouse, rat (Lewis et al., 1982; Noguchi et 
al., 2005) 
PGE2 Rat, mouse (Marshall et al., 1999) 
LTB4 Human, mouse (Freeland et al., 1988; 
Miyahara et al., 2009) 
LTC4 and D4 Human, mouse (Bartosz et al., 1998; Razin et 
al., 1982) 
PAF Mouse (Mencia-Huerta et al., 1983) 
Cytokines/chemokines/growth factors 
TNF Human, mouse (Hochdorfer et al., 2013; 
Oksaharju et al., 2009) 
IL-ȕ Human, mouse (Guma et al., 2010; Zhang et 
al., 2012a) 
IL-4 Human, mouse (Bradding et al., 1992; 
Sherman et al., 1999) 
IL-5 Human, mouse (Chiba et al., 2007; Lorentz et 
al., 1999) 
IL-6 Human, mouse (Hochdorfer et al., 2013; 
Kandere-Grzybowska et al., 
2006) 
IL-8 Human, mouse (Feoktistov and Biaggioni, 
1995; Oksaharju et al., 2009) 
IL-10 Human, mouse (Chiba et al., 2007; Ishizuka et 
al., 1999) 
IL-13 Human, mouse (Chiba et al., 2007; Toru et al., 
1998) 
IL-17 Human (Lin et al., 2011) 
IL-33 Mouse (Hsu et al., 2010) 
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IFN-Ȗ Rat (Gupta et al., 1996) 
TGF-ȕ Human, mouse (Kanbe et al., 1999) 
CCL11 (eotaxin) Mouse (Hogaboam et al., 1998) 
CCL2 Human, mouse (Toda et al., 2012; Venkatesha 
et al., 2005) 
CCL5 Human (Venkatesha et al., 2005) 
CXCL1/ CXCL2 Mouse (De Filippo et al., 2013) 
SCF Human (Zhang et al., 1998) 
VEGF Human, mouse (Jimenez-Andrade et al., 2013; 
Sismanopoulos et al., 2012) 
NGF Human, rat, mouse (Leon et al., 1994; Nilsson et 
al., 1997; Xiang and Nilsson, 
2000) 
PDGF Human (van Steensel et al., 2012) 
Free radicals 
ROS Human, rat, mouse (Swindle et al., 2004) 
Others  
Urocortin  Human (Kempuraj et al., 2004) 
IL: Interleukin; PG: Prostaglandin; LT: Leukotriene; PAF: Platelet activating factor; 
TNF: Tumor necrosis factor; IFN: Interferon; TGF: Transforming growth factor; CCL: 
CC chemokine ligand; CXCL: C-X-C chemokine ligand; SCF: Stem cell factor; VEGF: 
Vascular endothelial growth factor; NGF: Nerve growth factor; PDGF: Platelet-derived 
growth factor; ROS: Reactive oxygen species. 
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1.1.3 Role of mast cells in inflammatory diseases   
Mast cells are considered important effector cells in certain types of inflammation 
(Theoharides et al., 2012). Mast cells are especially vital in IgE-mediated immediate 
type I hypersensitivity because of their quick and massive release of preformed 
mediators, lipid-derived mediators and cytokine/chemokines (Theoharides and 
Kalogeromitros, 2006). The classical viewpoint is that mast cells are important effector 
cells in allergic responses, such as allergic asthma. However, mast cells also play a role 
in other inflammatory diseases whose pathogenesis does not involve IgE (Bot et al., 
2008).   
Allergic asthma is a common IgE-mediated chronic inflammatory disease of the 
airways, characterized by airway inflammation, bronchial hyperreactivity, and airway 
remodelling (Barnes, 2008). Mast cells may participate in all of these processes. 
Angiogenesis promoting factors, such as vascular endothelial growth factor (VEGF), 
from activated mast cells contribute to airway remodelling in asthma (Zanini et al., 
2007), which includes immune cell infiltration, mucus gland hypertrophy, and 
hyperplasia of epithelial cells and airway smooth muscle cells (Yuksel et al., 2013). Mast 
cells produce CC chemokine ligand (CCL)11 and histamine to attract eosinophils, 
another vital effector cell in allergic asthma responsible for both airway damage and 
remodelling (Shakoory et al., 2004). Histamine from mast cells causes smooth muscle 
contraction and may also promote mucus production by goblets cells (Huang et al., 
2013; Suzuki and Kou, 1983). Mast cells also contribute to airway smooth muscle 
contraction by producing PGs and LTs (Krell et al., 1981; Tamaoki et al., 1987).  
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Another contribution of mast cells to the development of allergic asthma is their 
connection to Th2 cell responses (Nagarkar et al., 2012) which are more involved in late 
phase reactions. Mast cells produce IL-4, IL-5, and IL-13 (Ho et al., 2007; Sewell et al., 
1998), which are among the most well characterized asthma-promoting Th2 cytokines. 
IL-4 plays a key role in initiation and amplification of Th2 responses and asthmatic 
reactions. IL-4 directs the polarization of naive helper T cells toward the Th2 subset by 
facilitating the expression of GATA-3, the crucial transcription factor for Th2 
differentiation (Seki et al., 2004). In addition, IL-4 promotes the production of IgE from 
B cells (Pene et al., 1988), which mediates the activation of mast cells through 
LQWHUDFWLRQZLWK)Fİ5, ,/-5 stimulates the production and terminal differentiation of 
eosinophils in the bone marrow and primes eosinophils to increase functional responses 
to lipid mediators, complements, and chemokines (Kuo et al., 2001; Takafuji et al., 
1991). Furthermore, IL-5 is required for the release of eosinophils from bone marrow to 
the peripheral blood (Wang et al., 1998). IL-13 promotes eosinophil production and 
differentiation by increasing local IL-5 and eosinophil-attracting CCL11 expression 
(Gessner et al., 2005). Furthermore, IL-13 directly promotes airway smooth muscle cell 
contractility (Farghaly et al., 2008). IL-4 and IL-13 were also reported to facilitate IgG1 
production (Lai and Mosmann, 1999) which may complex with inhaled antigen and 
DFWLYDWHGHQGULWLFFHOOVWKURXJKWKH)FȖUHFHSWRUWRSUomote allergic responses (Ishikawa 
et al., 2011). 
Mast cells also have a role in the development of inflammatory diseases that are not 
mediated by IgE. For example, heart mast cells, which reside predominantly in the 
shoulder region of human coronary atheroma, especially around nerve endings 
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(Kaartinen et al., 1994), are involved in the development of atherosclerosis, coronary 
inflammation, and cardiac ischemia (Bot et al., 2008). Mast cell proteases have been 
suggested to participate in neuroinflammation by activating microglia to produce TNF, 
IL-6, and ROS (Zhang et al., 2012b).  
)Fİ5,and mast cell activation 
)Fİ5,VWUXFWXUHDQGUHJXODWLRQRI)Fİ5,FHOOVXUIDFHH[SUHVVLRQ 
)Fİ5,LVDPXOWLPHULFFHOO-surface receptor to which the Fc region of IgE binds with 
KLJKDIILQLW\)Fİ5,H[LVWV DV WZR IRUPV trimeric and tetrameric molecules. Trimeric 
)Fİ5,LVIRUPHGIURPRQHĮDQGWZRȖFKDLQVZLWKQRȕFKDLQVSUHVHQWUHIHUUHGWRDV
ĮȖ 7ULPHULF )Fİ5, LV H[SUHVVHG on human antigen-presenting cells, including 
macrophages, myeloid dendritic cells, plasmacytoid dendritic cells, Langerhans cells, 
and eosinophils, but is not present on rodent cells (Kinet, 1999).The tetrameric form of 
)Fİ5, FRQWDLQV RQH Į-FKDLQ RQH ȕ-FKDLQ DQG D KRPRGLPHU RI Ȗ-chains linked by 
GLVXOSKLGHERQGVUHIHUUHGWRDVĮȕȖ)LJ17KHWHWUDPHULFIRUPRI)Fİ5,H[LVWVRQ
both human and rodent mast cells and basophils (Kraft and Kinet, 2007).  
7KHĮFKDLQRI)Fİ5,EHORQJVWRWKHLPPXQRJOREXOLQVXSHUIDPLO\ZKLFKFRQWDLQV
two extracellular immunoglobulin-related domains for IgE bindLQJ)Fİ5,ĮDOVRKDVD
transmembrane domain and a short cytoplasmic tail with no kinase activity and no 
immunoreceptor tyrosine-based activation motif (ITAM) domain (Fig. 1.1) (Kimura et 
al., 1996)7KHĮ-chain contains seven N-glycosylated sites required for proper folding in 
the endoplasmic reticulum (ER), transportation from ER to the Golgi complex, and cell 
VXUIDFHH[SUHVVLRQRI)Fİ5,(Letourneur et al., 1995).  
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7KHȕFKDLQRI)Fİ5,FRQWDLQVIRXUWUDQVPHPEUDQHGRPDLQVDQGWZRF\WRSODVPLF
tails. One of the tails has an ITAM sequence which functions as a tyrosine 
SKRVSKRU\ODWLRQ VLWH7KH Ȗ FKDLQKDV D VKRUW H[WUDFHOOXODU GRPDLQ D WUDQVPHPEUDQH
domain, and an ITAM-containing cytoSODVPLFWDLO3KRVSKRU\ODWHG,7$0VLQȕDQGȖ
chains recruit and activate the sarcoma (Src) homology 2 (SH2) domain containing 
intracellular signaling molecules such as spleen tyrosine kinase (Syk)7KHȖFKDLQ LV
also required for expression and proper fuQFWLRQRI FHOO VXUIDFH)Fİ5,EHFDXVH WKH Ȗ
FKDLQUHOHDVHVWKHĮFKDLQIURPthe ER by masking an ER-UHWHQWLRQPRWLILQWKHĮFKDLQ 
(Fig. 1.1) (Kimura et al., 1996).  
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Figure 1.1 6WUXFWXUHRIWHWUDPHULF)Fİ5, DQGELQGLQJRI,J(WR)Fİ5,A tetrameric 
)Fİ5,LVFRPSRVHGRIRQHĮFKDLQRQHȕFKDLQDQGWZRȖFKDLQVȕDQGȖFKDLQVFRQWDLQ
ITAM in cytoplasmic tails for tyrosine phosphorylation. IgE binds to the Į FKDLQ RI
)Fİ5, WKURXJK FRQVWDQW Cİ UHJLRQ IgE: imunoglobulin E; ITAM: immunoreceptor 
tyrosine-based activation motif. 
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The sequence of events leading to )Fİ5,FHOOVXUIDFHH[SUHVVLRQFDQEHGHVFULEHGDV
IROORZV7KHĮFKDLQ LVSURGXFHG LQ WKH(5LQDQ LPPDWXUHJO\FRV\ODWHGIRUPZKLFK
stays in the (5LQWKHDEVHQFHRIRWKHU)Fİ5,FKDLQV$IWHUSURSHUIROGLQJLQWKH(5DQG
assembly of the ĮȕDQGȖFKDLQVRUĮDQGȖFKDLQVLPPDWXUH)Fİ5,OHDYHVWKH(5DQG
HQWHUVWKH*ROJLFRPSOH[IRUWHUPLQDOJO\FRV\ODWLRQ0DWXUH)Fİ5,LVWKHQWUDQVSRUWHGWR
the cell surface by secretary YHVLFOHV7KHFHOOVXUIDFH)Fİ5, are routinely internalized 
back to endosomes for degradation in lysosomes (Kraft and Kinet, 2007).  
7KHFHOOVXUIDFHH[SUHVVLRQRI)Fİ5,FDQEHUHJXODWHGE\VHYHUDOIDFWRUV)LJ2). 
The ȕ-chain, which has four transmembrane domains, favors the maturation and stability 
RI WKH UHFHSWRU FRPSOH[ VR WKHȕ-chain may function as an amplifier of cell surface 
)Fİ5, H[SUHVVLRQ ,W LV UHSRUWHG WKDW WKH FHOO VXUIDFH H[SUHVVLRQ RI )Fİ5, LQ ĮȖ
expressing cells was significantly enhanced by introdXFWLRQRI)Fİ5,ȕ(Lin et al., 1996). 
$WUXQFDWHGȕ-chain variant which does not have a normal transmembrane domain and 
FDUER[\OWHUPLQXVȕ7 can be produced by alternative splicing. The incorporation of ȕ7
with DQĮ FKDLQ UHVXOWV LQGHJUDGDWLRQRI LPPDWXUH)Fİ5,FRPSOH[HV LQSURWHDVRPHV
(Donnadieu et al., 2003),QWURGXFWLRQRIȕ7LQWRĮȕȖ-expressing mast cells results in a 
VLJQLILFDQW GHFUHDVH LQ )Fİ5, FHOO VXUIDFH H[SUHVVLRQ (Ra et al., 2012). Another 
PRGXODWRURQ)Fİ5,FHOOVXUIDFHH[SUHVVLRQLV)Fİ5,OLJDQG,J(0RQRPHULF,J(ZDV
VKRZQ WR LQFUHDVH FHOO VXUIDFH H[SUHVVLRQ RI )Fİ5I by stabilizing the receptor and 
reducing internalization (Quarto et al., 1985; Yamaguchi et al., 1997).  
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Figure 1.2 5HJXODWLRQRI)Fİ5,cell surface expression. ĮȕDQGȖFKDLQVDUHSURGXFHG
in the ER and assembled into tetrameric form, which is then transported to the Golgi 
FRPSOH[IRUWHUPLQDOJO\FRV\ODWLRQ$IWHUWKDW)Fİ5,LVWUDQVSRUWHGWRthe cell surface. A 
truncated version of the ȕFKDLQȕ7FDQEHSURGXFHGLQthe ER by alternative splicing. 
7KHFRPSOH[RIĮDQGȕ7ZLOOEHGHJUDGHG LQ the SURWHDVRPH&HOO VXUIDFH)Fİ5, LV
constantly internalized in the endosome and transported to the proteasome for 
GHJUDGDWLRQ7KHELQGLQJRI,J(WR)Fİ5,FDQVXSSUHVVWKHUHFHSWRULnternalization. ER: 
endoplasmic reticulum; ȕ7WUXQFDWHGȕFKDLQ  
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%LRORJLFDOIXQFWLRQVRIWHWUDPHULF)Fİ5, 
7KH PRVW GRFXPHQWHG IXQFWLRQ RI WHWUDPHULF )Fİ5, LV DV WKH NH\ SDUWLFLSDQW LQ
IgE-mediated mast cell activation and allergic reaction (Ishizuka et al., 1996). Upon 
cross-linking of IgE-ERXQG )Fİ5, E\ ELYDOHQW RU PXOWLYDOHQW DQWigens, mast cells are 
activated to gradually release preformed mediators, lipid-derived mediators, and 
cytokines/chemokines, which mediate early and late-phase allergic reactions (Liu et al., 
2005) 7KH OHYHO RI )Fİ5, H[SUHVVLRQ RQ WKH FHOO VXUIDFH GHWHUPLQHV WKH PDVW FHOO¶V
response to IgE/antigen (Andrews et al., 2009). IgE-mediated allergic reactions cannot 
EHHVWDEOLVKHGLQ)Fİ5,ĮRU)Fİ5,ȕ-deficient mice (Ra et al., 2012; Taube et al., 2004). 
Without antigen, IgE alone can lead to low level receptor cross-linking, signal 
transduction, and mediator release (Kalesnikoff et al., 2001). Mast cell survival was also 
reported to be enhanced by IgE alone. The possible mechanism is through the activation 
of MAPK and Akt SDWKZD\V0DVWFHOOUHVSRQVHVPHGLDWHGE\WHWUDPHULF)Fİ5,have 
direct and in-direct effects on parasite killing by producing ROS and facilitate 
anti-parasitic functions of other immune cells, such as eosinophils, NK cells, and 
neutrophils.  
)Fİ5,VLJQDOLQJLQPDVWFHOOV 
The cross-OLQNLQJ RI )Fİ5, E\ DQWLJHQ WKURXJK ,J( FDQ LQLWLDWH D FRPSOH[
intracellular signaling cascade which results in mediator release. New adaptors, kinases, 
and negative regulators have been discovered continuously in recent years.   
16 
 
1.2.3.1 Initial phosphorylation 
7KHILUVWHYHQWDIWHU)Fİ5,FURVV-OLQNLQJLVWKHSKRVSKRU\ODWLRQRI,7$0VLQWKHȕ
DQGȖFKDLQV,WLVJHQHUDOO\DFFHSWHGWKDWWKH6UFfamily protein tyrosine kinase Lyn, an 
acylated protein on membrane, LVUHVSRQVLEOHIRU)Fİ5,SKRVSKRU\ODWLRQ(Bugajev et al., 
2010).  
Currently, three models for this process have been proposed (Bugajev et al., 2010). 
The first model is the transphosphorylation model. Lyn is non-covalently associated 
with a non-SKRVSKRU\ODWHGȕFKDLQEXW,7$0LQWKHȕFKDLQGRHVQRWKDYHDFFHVVWRWKH
active site of Lyn. Receptor cross-linking allows Lyn to phosphorylate ITAMs of 
neighboring receptors. Another model, the lipid raft model, proposes that 
glycosylphosphatidylinisotol (GPI)-anchored proteins, and acylated proteins (such as 
Lyn) are concentrated in specific membrane regions termed as lipid rafts which are in a 
liquid-ordered state and provide a relatively stable platform for membrane signaling and 
trafficking (Sonnino and Prinetti, 2013). The lipids in a membrane may exist in three 
different states. In a solid-ordered state, lipid chains are tightly packed and move slowly. 
A liquid-disordered state is featured with loosely packed and fast-moving lipid chains. A 
liquid-ordered state is supposed to be more stable than the liquid-disordered state with 
more tightly organized and extended lipid chains (Heberle and Feigenson, 2011).The 
concept of lipid rafts will be described later in section 1.3. Lipid rafts enable the quick 
access and recruitment of elements needed for receptor signaling, such as receptors, 
membrane-bound kinases, and adaptors (Brown, 2006) ,Q WKLV PRGHO )Fİ5, LV
considered to be separated from active Lyn residing in lipid raft domains of resting cells. 
After receptor cross-OLQNLQJDJJUHJDWHG)Fİ5,LVFORVHHQRXJKWREHSKRVSKRU\ODWHGE\
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Lyn. The third model emphasizes the interplay of protein tyrosine kinase (PTK) and 
protein tyrosine phosphatase (PTP), which are known to be expressed by mast cells 
(Akimoto et al., 2009). PTP plays a counteractive role against PTK. The balance 
between PTK and PTP determines the phosphorylation status. In this model, PTP is 
considered as a guard maintaining the threshold oI )Fİ5, W\URVLQH SKRVSKRU\ODWLRQ
$IWHU)Fİ5,FURVV-linking, PTP activity is suppressed, thus phosphorylation of ITAMs in 
ȕDQGȖFKDLQVFDQEHFDWDO\]HGE\37. (Simons and Toomre, 2000). Superoxide and 
hydrogen peroxide, which are ROS and known inhibitors of PTP, have been shown to 
LQLWLDWHHDUO\VLJQDOLQJHYHQWVLQWKH)Fİ5,SDWKZD\LQPDVWFHOOV(Heneberg and Draber, 
2005).  
1.2.3.2 Signal transduction 
After initial phosphorylation of )Fİ5,, the signal cascade proceeds in the cytoplasm 
and involves interactions between kinases, adaptors, scaffolds, and small G proteins 
(Fig. 1.3). Phosphorylated ITAMs function as docking and activating sites for SH2 
domains containing protein tyrosine kinases, mainly the Src family kinases Lyn and Fyn, 
as well as Syk family kinase Syk (Johnson et al., 1995). Fyn phosphorylates growth 
factor receptor-bound protein 2 (Grb2)-associated-binding protein 2 (GAB2), which 
facilitates activation of phosphoinositide 3-kinase (PI3K) (Xie et al., 2002). PI3K 
activation leads to phosphatidylinositol-3,4,5-trisphosphate (PIP3) production, which 
then recruits and activates protein kinase B (PKB, also known as Akt). Activated Akt 
then regulates activity of down-stream target proteins including B cell lymphoma-2 
-associated death promoter (BAD), caspase-9, NF-ț%JO\FRJHQV\QWKDVHNLQDVH-3, and 
mammalian target of rapamycin (mTOR), which modulates cell proliferation, 
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differentiation, metabolism and apoptosis (Kim et al., 2008). PI3K also mediates 
activation of phosphoinositide-dependent protein kinase 1 (PDK1) and protein kinase C 
(PKC). PKC is responsible for degranulation and activation of NF-ț% WUDQVFULSWLRQ
factor (Windmiller and Backer, 2003). Syk activates PKC, as well as linker for activation 
of T cells (LAT) and the SH2 domain containing leukocyte protein of 76 kDa (SLP76) 
which are adaptor proteins forming large signaling complexes with other molecules such 
as the phospholipase C-Ȗ (PLC-Ȗ) (Siraganian et al., 2010). PLC-Ȗ K\GURO\]HV
phosphatidylinositol 4,5-bisphosphate (PIP2) to produce second messengers 
diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). PLC-Ȗ FDQ DOVR EH
activated by Bruton's tyrosine kinase (BTK), which is a downstream event of PIP3 
production (Tkaczyk et al., 2003). DAG can also activate PKC (Teixeira et al., 2003). 
IP3 binds to receptors on the ER and causes calcium release from the ER which can 
activate PKC, contribute to degranulation, and activate nuclear factor of activated 
T-cells (NFAT), a transcription factor (Taylor and Thorn, 2001). LAT also mediates the 
activation of another adaptor protein, Grb2, and the guanine-nucleotide-exchange factor 
son-of-sevenless homologue (SOS) which leads to the activation of mitogen-activated 
protein (MAP) kinases (p38, c-Jun N-terminal kinase (JNK) and extracellular 
signal-regulated kinase (ERK)) and, ultimately, the activation of activator protein-1 
(AP)-1 transcription factor (Saitoh et al., 2000). ERK can activate cytoplasmic 
phospholipase A2 (cPLA2) which frees arachidonic acid (AA, 20:4 n-6), 
eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) from 
phospholipids in plasma membranes (Fujishima et al., 1999). Eicosanoids can be 
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produced from AA or EPA under a series of oxidative enzymes, including 
cyclooxygenases (COX) and lipoxygenases (LOX) (Fig. 1.3) (Boyce, 2005).  
)Fİ5, VLJQDOLQJ FDQ EH UHJXODWHG E\ inhibiting signals delivered by )FȖ5,,%, 
)FĮ5, and CD63. The IgG receptor )FȖ5,,% can recruit SH2-containing inositol 
5-phosphatase (SHIP) through their immunoreceptor tyrosine-based inhibition motif 
(ITIM) (Ott et al., 2002; Tkaczyk et al., 2004)7KH,J$UHFHSWRU)FĮ5,can LQKLELW)Fİ5,
signaling by recruiting SHP-1, a SH2-containing tyrosine-specific protein phosphatase, 
which is expressed ubiquitously in the body (Pasquier et al., 2005).  Antibodies against 
CD63, a tetraspanin molecule on the cell surface, were reported to inhibit mast cell 
degranulation by disrupting the GAB2-PI3K pathway (Kraft et al., 2005).    
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Figure 1.3 'LDJUDPRI)Fİ5,VLJQDOLQJThe binding RIDQWLJHQWR)Fİ5,-bound IgE 
causes receptor cross-OLQNLQJ ZKLFK OHDGV WR SKRVSKRU\ODWLRQ RI ,7$0V LQ ȕ DQG Ȗ
chains by Lyn. Phosphorylated ITAMs function as docking and activating sites for Syk. 
Phosphorylated Syk then activates PKC, which is responsible for degranulation and 
activation of NF-ț%6\NDOVRSKRVSKRU\ODWHV/$7ZKLFK IDFLOLWDWH WKHDFWLYDWLRQRI
PLC-ȖWRJHQHUDWH'$*DQG,3IURP3,3'$*DFWLYDWHV3.&,3FDXVHVFDOFLXP
release from ER. LAT also activates another adaptor protein, Grb-2, which leads to 
activation of MAP kinases, ERK, JNK and P38. ERK activates cPLA2 which free AA 
and EPA from plasma and nuclear membrane. Eicosanoids can be generated from AA 
and EPA. AA: Arachidonic acid;  AP-1: Activator protein 1; cPLA2: Cytosolic 
phospholipase A 2; DAG: Diacylglycerol; EPA: Eicosapentaenoic acid; ER: 
Endoplasmic reticulum; ERK: Extracellular signal-regulated kinase; Grb2: Growth 
factor receptor-bound protein 2; IP3: Inositol trisphosphate; ITAM: Immunoreceptor 
tyrosine-based activation motif; JNK: C-Jun N-terminal kinase; LAT: Linker of 
Activated T cells; NFAT: Nuclear factor of activated T-cells; NF-ț%Nuclear factor 
kappa-light-chain-enhancer of activated B cells; PIP2: Phosphatidylinositol 
4,5-bisphosphate; PKC: Protein kinase C; PLC: Phospholipase C; Syk: Spleen tyrosine 
kinase. 
. 
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1.3 Lipid rafts in mast cell biology 
1.3.1 Concept of lipid rafts 
Lipid rafts are specific membrane microdomains that contain high levels of 
cholesterol, sphingolipid, transmembrane proteins, and GPI-anchored proteins on the 
outer leaflet and acylated proteins on the inner leaflet (Fig. 1.4) (Calder and Yaqoob, 
2007). Lipid rafts can be found in plasma membranes and intracellular membranes like 
the Golgi complex in all cell types (Nichols et al., 2001). Examples of GPI-anchored 
proteins that are associated with lipid rafts include CD14, CD80, and Thy-1, which are 
co-receptor, co-stimulatory molecule, and adhesion molecule (Clatza et al., 2003; 
Deininger et al., 2003; Schmitz and Orso, 2002). Lipid rafts function as platforms for 
membrane signaling and trafficking (Hanzal-Bayer and Hancock, 2007; Simons and 
Toomre, 2000). The plasma membrane is the place where cells detect signals from the 
extracellular environment. Lipid rafts are thought to facilitate the membrane signaling 
with harboured molecules such as receptors, adaptors, kinases and lipids required for 
signaling initiation and transduction. Membrane trafficking allows material 
transportation among cellular organelles, cell surface and extracellular environment 
(Cheung and de Vries, 2008). Fusion of lipid raft domains may contribute to this 
process (Alonso and Millan, 2001).   
The classic fluid mosaic model of membranes has been challenged for years and 
some of the concept has been proven untrue. The distribution of membrane molecules 
seems to not be random, but is organized in some way. In the 1990s, low density 
detergent-resistant membrane regions were isolated (Brown and Rose, 1992), which 
formed the basis of the lipid raft concept. Lipid analysis has shown that lipid rafts are 
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rich in sphingolipid and cholesterol, and the phospholipids in lipid rafts contain higher 
levels of long chain saturated fatty acids compared to non-raft regions (Fig. 1.4) 
(Brown and London, 2000). As a result, lipid rafts are in a more ordered state than 
non-raft regions, and the fluidity is lower. Lipid rafts are characterized by a high 
melting temperature and insolubility in non-ionic detergents (London and Brown, 
2000). Lipid rafts are also dynamic, which means their components are moving in and 
out of rafts constantly (Gupta and DeFranco, 2003). Lipid rafts are considered to be 
variable in terms of stability, size, shape, and composition (Rajendran and Simons, 
2005).  
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Figure 1.4 Structure of lipid rafts in cell membranes. Lipid rafts contain high levels 
of cholesterol, sphingolipid, transmembrane proteins, GPI-anchored proteins and 
acylated proteins. Rafts are considered to be packed more tightly than non-raft regions 
and are in a liquid-ordered state. GPI: glycosylphosphatidylinositol.  
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Some methods have been established to isolate and investigate lipid rafts. A 
common method to isolate lipid rafts is density gradient flotation using cold non-ionic 
detergents such as Triton X-100 based on their insolubility in non-ionic detergents 
(Brown, 2002). Flotillin, CD90 (Thy-1), Lyn, and monosialotetrahexosylganglioside 
(GM1) are common lipid raft markers used in research (Zajchowski and Robbins, 
2002). The size of the rafts is estimated to be between 1 and 1,000 nanometres 
(Lingwood and Simons, 2010). Rafts can be visualized with fluorescence microscopy, 
typically using fluorophore-conjugated cholera toxin B to label GM1 (Brown, 2002). 
Western blot analysis is the most commonly used technique to detect protein 
expression in lipid rafts (Brown, 2002). Methyl-ȕ-cyclodextrin (MBCD), a 
cholesterol-binding carbohydrate molecule, was used extensively to evaluate the role of 
lipid rafts in the biology of many cell types, including T cells, B cells, mast cells, 
breast cancer cells and more (Ostrom and Liu, 2007). However, MBCD is not specific 
for cholesterol in lipid rafts. Although rafts contain high level of cholesterol, 
cholesterol is actually distributed throughout the membrane and inside the cell. MBCD 
actually depletes all cholesterol inside the cell or on the cell membrane (Brown, 2002). 
Another cholesterol-depleting method is to use 3-hydroxy-3-methyl-glutaryl-CoA 
reductase inhibitors like simvastatin to suppress cholesterol synthesis. Simvastatin is 
also not specific for cholesterol in lipid rafts (Nawarskas, 2005).   
There is still debate on the existence and nature of lipid rafts because methods for 
isolating and studying rafts are limited which has restricted comprehensive research 
(Patel and Insel, 2009). One of the biggest arguments against lipid rafts is that the nature 
of the isolated material varies using different detergents or different concentrations of 
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the same detergent, leading to the possibility that artifacts are being created (Radeva and 
Sharom, 2004). However, detergent-free isolation of lipid rafts has been reported 
(Macdonald and Pike, 2005). Another controversy is that rafts were originally reported 
to be isolated using triton-X 100 in cold temperatures (4°C) only, but not at 37°C 
(London and Brown, 2000). However, the addition of cations was later found to allow 
the isolation of rDIWV DW Û& (Chen et al., 2009). Using fluorescence microscopy, 
GPI-anchored folate receptors were shown to be localized in membrane regions that are 
not soluble in non-ionic detergents in live Chinese hamster ovary cells, indicating that 
rafts exist in living cells (Varma and Mayor, 1998). However, it is still not fully clear 
whether, or by how much, detergent expands pre-existing rafts.  
1.3.2 Function of lipid rafts in immune cell signaling  
One of the most important role of lipid rafts on the cell surface is mediating the  
signaling pathways initiated by antigens, growth factors, morphogens, and integrins 
(Simons and Toomre, 2000). Lipid rafts function as a platform for receptor signaling 
with concentrated molecules needed for signal transduction. In addition, inhibitory 
enzymes, such as phosphatases, which reside in non-raft regions, are blocked from 
influencing signaling (Simons and Toomre, 2000). Thus, lipid rafts allow for more 
efficient access of receptors to their ligands and facilitate further signal transduction. 
There are three models for the role of lipid rafts in the initiation of signaling (Simons and 
Toomre, 2000; Staubach and Hanisch, 2011). First, receptors and adaptors are 
concentrated in rafts. When the ligands are present, receptors will be cross-linked. 
Second, the presence of ligands results in the partitioning of receptors in lipid rafts, 
which facilitates the binding of ligands to their receptors. Third, clustering of receptors, 
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adaptors, or cytoskeleton elements causes the fusion of small rafts to form big rafts 
which have a greater accumulation of receptors, kinases, and adaptors.  
The most extensively studied receptors in lipid raft research are T cell receptors 
7&5%FHOOUHFHSWRUV%&5DQG)Fİ5,ZKLFKDUHDOOPXOWL-chain receptors with no 
intrinsic kinase activity in the intracellular tails, but which contain ITAMs. The 
mediating role of lipid rafts in the signaling of receptors with intrinsic kinase activity, 
such as the insulin receptor, was also shown in some studies (Morino-Koga et al., 2013). 
Besides signal transduction in adaptive immune cells, lipid rafts also function similarly 
in innate immune cells. TLR4 and CD 14, which is a GPI-anchored protein and functions 
as a co-receptor of TLR 4 to detect lipopolysaccharides (LPS), were found to be 
concentrated in lipid rafts of macrophages (Olsson and Sundler, 2006).  
1.3.3 Role of lipid rafts in mast cells 
Lipid rafts have been confirmed to be present in mast cells by numerous studies 
(Silveira et al., 2011). Some of the lipid raft components were reported to be important in 
maintaining mast cell morphology and mast cell development. Ganglioside (a raft 
component) deficiency leads to morphological changes of RBL-2H3 cells (Silveira e 
Souza et al., 2010) which are rat basophilic leukemia cells used extensively in mast cell 
research. After depletion of gangliosides, RBL-2H3 cells change from spindle to round 
shape and are smaller (Silveira e Souza et al., 2010). As membrane domains, there is 
compelling HYLGHQFH VKRZLQJ WKDW OLSLG UDIWV DUH LQYROYHG LQ )Fİ5,-mediated 
endocytosis and signal transduction in mast cells, which will be discussed below.  
27 
 
1.3.3.1 Endocytosis 
Receptors on cell membranes are constantly internalized and replaced by newly 
formed receptors (Gao et al., 2005). It was reported that ubiquitin ligases Cbl and Nedd4 
DUHUHFUXLWHG LQWR OLSLGUDIWVDIWHUPDVWFHOODFWLYDWLRQPHGLDWHGE\)Fİ5, (Lafont and 
Simons, 2001)&EODQG1HGGPD\ IXQFWLRQ WRPHGLDWH)Fİ5,XELTXLWLQDWLRQZKLFK
provides a sorting signal. Ubiquitin-WDJJHG)Fİ5,LVLQWHUQDOL]HGWKURXJKFODWKULQ-coated 
vesicles and transported in the endosomes to the lysosomes for degradation (Fattakhova 
et al., 2009). Interestingly, in stimulated mast cells, GD1b (a ganglioside) in lipid rafts 
was VKRZQWREH LQWHUQDOL]HG WRJHWKHUZLWK)Fİ5, LQ WKHVDPHYHVLFOHDQGIROORZWKH
same path to the lysosomes (Oliver et al., 2007). In addition, GD1b deficiency 
suppressed receptor ubiquitination and endocytosis in mast cells (Mazucato et al., 2011). 
These resultV LQGLFDWH WKDW OLSLGUDIWVPD\QRWRQO\IDFLOLWDWH WKH WDJJLQJRI)Fİ5,IRU
internalization, but also function as the site of vesicle formation.  
1.3.3.2 Signal transduction 
,Q VWLPXODWHG FHOOV )Fİ5, ZDV shown to be recruited to lipid rafts quickly and 
participate in the extensive protein-SURWHLQLQWHUDFWLRQVLQ)Fİ5,VLJQDOLQJ(Field et al., 
1997). However, the other action models described above (section 1.3.2) may also exist. 
The models are not exclusive.  
Many lipiGUDIWFRPSRQHQWVKDYHEHHQVKRZQWRUHJXODWH)Fİ5,VLJQDOLQJ/\QLV
concentrated in lipid rafts and is more active in rafts than in non-raft regions, possibly 
because lipid rafts can protect Lyn from dephosphorylation by  phosphatase (Young et 
al., 2003). Some raft components were found to regulate Lyn activity, such as flotillin-1. 
Flotillin-1 knockdown RBL-2H3 cells showed impaired Lyn activity with reduced 
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)Fİ5,SKRVSKRU\ODWLRQFDOFLXPPRELOL]DWLRQDQG(5.DFWLYDWLRQDIWHUFHOODFWLYDWLRQ
WKURXJK)Fİ5,(Kato et al., 2006). Besides protein components, lipid components in lipid 
rafts were also shown to modulate signaling. Cholesterol is required for phosphorylation 
RI )Fİ5, 0%&' WUHDWPHQW VLJQLILFDQWO\ UHGXFHG W\URVLQH SKRVSKRU\ODWLRQ RI )Fİ5,
induced by IgE/antigen and suppressed mediator release from mast cells, possibly by 
GLVUXSWLQJ WKH LQWHUDFWLRQEHWZHHQ)Fİ5, DQG/\Q (Sheets et al., 1999) Į-Galactosyl 
derivatives of ganglioside GD1b were found to down-regulate mast cell activation by 
promoting phosphatidylinositol hydrolysis and PKC redistribution (Field et al., 2000). 
These results indicate that lipid raft property KDVDJUHDWLQIOXHQFHRQ)Fİ5,VLJQDOLQJ
and mast cell activation. 
1.4 n-3 Polyunsaturated Fatty Acids (PUFAs)  
1.4.1 Nomenclature, metabolism, and functions of fatty acids 
Fatty acids are a group of hydrophobic molecules that are composed of hydrogen 
DQGFDUERQDWRPVZLWKDPHWK\OJURXSDWRQHHQGȦRUQHQGRIWKHPROHFXOHDQGD
carboxyl group at the other end (Das, 2006a). If a fatty acid contains no carbon-carbon 
double bonds, it is called saturated. If a fatty acid contains one or more-than-one double 
bond, it is called a monounsaturated or PUFAs, respectively. Short-chain fatty acids 
contain fewer than six carbon atoms in the chain. Medium chain fatty acids contain 6±12 
carbon atoms. The backbones of long chain fatty acids and very long chain fatty acids 
have 13-22 and more than 22 carbons atoms, respectively. The naturally formed double 
ERQGKDVFLVFRQ¿JXUDWLRQZKLFKPHDQVK\GURJHQDWRPVRQERWK VLGHRI WKHGRXEOH
bond are pointed in the same direction. Thus, double bonds in natural fatty acids cause 
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the molecule to kink in its molecular shape (Das, 2006b). According to the position of 
the first double bond from the n Ȧ end, PUFAs can be classified as n-3, n-6 and n-9 
PUFAs, whose first double bond is between the number 3 and 4, 6 and 7, 9 and 10 carbon 
from QȦHQGrespectively (Fig. 1.5) (Simopoulos, 2000). 
During digestion, free fatty acids are absorbed in the small intestine and transported 
to the blood through lymphatic vessels. Fatty acids are then taken up into cells by fatty 
acid-binding proteins and transported inside cells. Intracellular fatty acids can be 
transformed to acyl-CoA and carried by acyl-CoA binding protein to mitochondria or 
peroxisomes for ATP production. Acyl-CoA can also go to the endoplasmic reticulum 
for esterification to produce other types of lipids such as cholesterol, phospholipids, and 
triglycerides. Twenty carbon n-3 and n-6 PUFAs can be converted to eicosanoids by 
COX and LOX enzymatic pathways (Calder, 2010).  
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Figure 1.5 Representatives of n-3, n-6, and n-9 PUFAs. The position of first double 
ERQGIURPQȦHQGLVEHWZHHQthe number 3 and 4 carbon in n-3 PUFAs, 6 and 7 carbon 
in n-6 PUFAs, and 9 and 10 carbon in n-9 PUFAs.  
,  
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In general, fatty acids have four functions.  
1) Three fatty acid chains and one glycerol form one molecule of triglyceride, 
which is the most efficient way to store energy in biology molecules. One gram of 
triglyceride stores 9 kcal energy. In contrast, one gram of protein and carbohydrate 
contain a similar amount of energy, 4 kcal. Alcohol can produce 7 kcal/g (Berg JM, 
2002).  
2) Fatty acids are building blocks for some biomolecules such as acylation of 
proteins and lipids forming the basic structure of membrane phospholipid bilayer 
(Holthuis and Levine, 2005). Thus, fatty acids are important for membrane 
structure and function.  
3) Twenty carbon chain n-3 and n-6 PUFAs can be transformed under enzyme 
catalysis to eicosanoids, including PGs, LTs, thromboxanes, resolvins, protectins 
and lipoxins, which are signaling molecules modulating a broad range of body 
functions, such as body temperature, immune function, wound healing, pain, and 
smooth muscle relaxation/contraction (Calder, 2010; Fan et al., 2013).  
4) Fatty acids can modulate gene expression directly. Free fatty acids can bind 
to certain G-protein-coupled receptors on the cell surface, initiate signaling, and 
modulate gene transcription. Fatty acids can also bind to peroxisome 
proliferator-activated receptor (PPAR Į DQG Ȗ ZKLFK IXQFWLRQ WRJHWKHU ZLWK
retinoic-X receptors as nuclear receptors and regulate gene expression in 
inflammation, OLSRJHQHVLV OLSRSURWHLQ DVVHPEO\ ȕ-oxidation, adipocyte 
differentiation, glucose metabolism, and insulin sensitivity (Varga et al., 2011). 
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1.4.2 n-3 PUFAs: effects and mechanisms 
Į-Linolenic acid (ALA) is the precursor of other n-3 PUFAs (Calder, 2013). ALA is 
an essential fatty acid, which means that it cannot be synthesized de novo in the body 
(Das, 2006a). EPA and docosahexaenoic acid (DHA) are the main bioactive forms of n-3 
PUFAs in the body, generated from ALA by enzyme-catalyzed elongation, desaturation, 
DQGȕ-oxidation (Su, 2008). The structure of ALA, EPA and DHA was shown in Fig. 
1.6. The n-3 PUFAs were listed in Table 1.2. In mammals, n-3 PUFAs cannot be 
synthesized de novo (Harel et al., 2001), and must be obtained from the diet or produced 
from ALA. Fish, shellfish, seed oil and nuts are good food resources of n-3 PUFAs 
(Deckelbaum and Torrejon, 2012). 
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Table 1.2 List of n-3 PUFAs  
Common name Lipid 
name 
Chemical name Formula/ 
molecular weight 
Hexadecatrienoic acid 16:3 
n-3 
all-cis-7,10,13-hexadecatrienoic  
acid 
C16H26O2/250.376 
Į-Linolenic acid (ALA) 18:3 
n-3 
all-cis-9,12,15-octadecatrienoic  
acid 
C18H30O2/278.430 
Į-Parinaric acid 18:4 
n-3 
all-cis-9,11,13,15-octadecatetraenoic 
acid 
C18H28O2/276.414 
Stearidonic acid 18:4 
n-3 
all-cis-6,9,12,15-octadecatetraenoic  
acid 
C18H28O2/276.414 
Eicosatrienoic acid 20:3 
n-3 
all-cis-11,14,17-eicosatrienoic 
acid 
C20H34O2/306.483 
Eicosatetraenoic acid 20:4 
n-3 
all-cis-8,11,14,17-eicosatetraenoic  
acid 
C20H32O2/304.467 
Eicosapentaenoic acid 
(EPA) 
20:5 
n-3 
all-cis-5,8,11,14,17-eicosapentaenoic 
acid 
C20H30O2/302.451 
Docosapentaenoic acid 
(DPA) 
22:5 
n-3 
all-cis-7,10,13,16,19-docosapentaenoic 
acid 
C22H34O2/330.504 
Docosahexaenoic acid 
(DHA) 
22:6 
n-3 
all-cis-4,7,10,13,16,19-docosahexaenoic 
acid 
C22H32O2/328.488 
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The health-promoting role of long chain n-3 PUFA, especially EPA and DHA, are 
well documented in a broad range of health and disease conditions. The consumption of 
EPA and DHA is associated with a lower risk of cancer, hyperlipidemia, cardiovascular 
diseases, hypertension, and neurodegenerative diseases (Siriwardhana et al., 2012). The 
low incidence of heart disease in the Inuit and Eskimos populations has been attributed 
to their high seafood intake, diets rich in n-3 PUFAs (Dewailly et al., 2001; Dyerberg et 
al., 1978; Holub, 1988). The regulatory functions of n-3 PUFAs on the immune system 
are also well known. N-3 PUFAs were reported to modulate activation of many immune 
cells, including T cells, B cells, mast cells, and basophils (Calder, 1997; Wu and 
Meydani, 1998). The multiple effects of n-3 PUFAs are the results of multiple 
mechanisms, summarized as follows:  
1) As a membrane component, n-3 PUFAs are believed to regulate membrane 
structure and properties and, therefore cell function (Jump, 2002). EPA and DHA 
supplementation were reported to decrease AA and increase EPA/DHA levels in 
membranes, whole cells, and tissues, resulting in alteration in membrane structure and 
fluidity, protein distribution in membrane, and signal transduction (Anderson and Ma, 
2009; Jump, 2002). In recent years, some studies have shown that n-3 PUFAs can reduce 
T cell response by altering lipid raft composition. In a study in human T cells, DHA 
supplementation was shown to increase ALA, docosapentaenoic acid (DPA, n-3), and 
DHA levels in lipid rafts, resulting in a decreased n-6/n-3 ratio in lipid rafts (Li et al., 
2005). Subsequently, IL-2 receptor Į(IL-2RĮ) expression on cell surface was decreased. 
In addition, IL-5ĮȕDQGȖZHUHUHORFDWHGWRQRQ-raft regions after DHA treatment (Li 
et al., 2005). Furthermore, signal transducer and activator of transcription (STAT) 5a 
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and STAT5b recruitment to lipid rafts were inhibited (Li et al., 2005). In human breast 
cancer cells, EPA and DHA treatment decreased sphingomyelin, cholesterol, and DAG 
content and increased ceramide levels in lipid rafts (Schley et al., 2007). Epidermal 
growth factor receptor (EGFR) expression in lipid rafts was disrupted. EPA and DHA 
treatment inhibited breast cancer cell proliferation by over-promoting phosphorylation 
of both EGFR and p38 kinase, which function to activate AP-1 transcription factor 
(Schley et al., 2007). 
2) EPA functions as a precursor for eicosanoids (Fig. 1.7). The main eicosanoid 
precursor in the body is AA. Eicosanoids from AA have high pro-inflammatory 
potential, while those from EPA have low pro-inflammatory potential (Calder, 2006). 
Eicosanoids can be made by oxidation of 20-carbon n-3 (EPA) and n-6 (AA and 
dihomo-Ȗ-linolenic acid (DGLA)) PUFAs (Tapiero et al., 2002). However, 3-series PGs 
and 5-series LTs from EPA are weaker than AA-derived 2-series PGs and 4-series LTs 
at promoting vasodilation, smooth muscle contraction, vascular permeability, and 
leukocyte recruitment (Calder, 2006). E-series resolvins from EPA and protectins and 
D-series resolvins from DHA are anti-inflammatory (Fig. 1.7). In addition, there is 
competition between n-3 PUFAs and n-6 PUFAs as substrates for oxidation by COX and 
LOX, the critical enzymes for eicosanoid generation (de Roos et al., 2009), reducing the 
synthesis of highly pro-inflammatory eicosanoids from AA. PGs (1-series) from DGLA 
are anti-inflammatory, however the level of DGLA in body is about 10-fold lower than 
AA (Umeda-Sawada et al., 2006).  
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Figure 1.7 Eicosanoids derived from PUFAs. DGLA, AA and EPA are all precursors 
of eicosanoids. Two-series PGs and 4-series LTs from AA have high pro-inflammatory 
potential. Three-series PGs and 5-series LTs from EPA have low pro-inflammatory 
potential. One-series PGs from DGLA, E-series resolvins from EPA and protectins and 
D-series resolvins from DHA are anti-inflammatory; LTs: leukotrienes; PGs: 
prostaglandins. 
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3) Two cell surface receptors, both G-protein-coupled receptors, for n-3 PUFAs 
have been identified. G-protein-coupled receptor (GPR) 40 can bind to a broad range of 
medium and long chain free fatty acids (Briscoe et al., 2003; Mancini and Poitout, 2013). 
GPR40 is highly expressed in human brain and pancreas (Yonezawa et al., 2013). 
GPR40 has a regulating function in pain (Nakamoto et al., 2012) and insulin secretion of 
SDQFUHDWLFȕ-cells (Salehi et al., 2005). In immune cells, GPR40 was only detected in 
monocytes (Mancini and Poitout, 2013).  
GPR120 is another receptor to which long chain free fatty acids, with preference for 
PUFAs, bind (Oh and Olefsky, 2012). GPR120 is expressed in human adipose tissue, 
colon, lung, trachea, and macrophages (Oh and Olefsky, 2012; Oh et al., 2010). Using 
human epithelial colorectal adenocarcinoma cells Caco-2, GPR120 was shown to bind 
both n-3 (EPA, DHA) and n-6 (AA) PUFAs (Mobraten et al., 2013). EPA, DHA, and 
AA all enhanced intracellular calcium levels with similar efficacy, but the response of 
calcium to AA was quicker than DHA and slower than EPA. EPA, DHA and AA all 
activate ERK in Caco-2 cells, but AA had the slowest response (Mobraten et al., 2013). 
These results indicate that n-3 and n-6 PUFAs are all GPR120 ligands, but initiate 
similar signaling pathways with different potency. GPR120 was shown to modulate 
inflammatory responses. It was reported that GW9508, a GPR120 agonist, and DHA 
suppressed LPS-induced TNF and IL-6 production in RAW 264.7 cells (mouse 
leukaemic monocyte macrophage cells) and primary intraperitoneal macrophages (Oh et 
al., 2010). The effect was diminished after GPR120 knockdown.  
4)  n-3 PUFAs can activate or interfere with the activation of some transcription 
factors. They can also regulate gene transcription directly through binding to PPARs 
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(Zuniga et al., 2011) which are nuclear receptors that can be activated by a large range of 
fatty acids and fatty acid derivatives. PPARs regulate lipid metabolism, inflammation, 
immune function, and cell proliferation and differentiation (Peters et al., 2012). PPARs 
can also interact with NF-ț%DQG OLPLW LWV WUDQVORFDWLRQ WR WKHQXFOHXVThus, PPARs 
have an inhibiting effect on production of inflammatory mediators such as TNF and 
IL-ȕ (Chinetti et al., 2003). PPARs are expressed in adipose tissue, liver, pancreas, 
muscle, heart, macrophages, dendritic cells, lymphocytes, and mast cells (Linard and 
Souidi, 2010).  
1.4.3 n-3 PUFAs, inflammation and allergy  
In the last decade, many studies have been conducted to explore the relationship 
between n-3 PUFAs and inflammatory diseases. In a study conducted in rheumatoid 
arthritis patients, a significant improvement in symptoms was reported after 3 months of 
fish oil supplementation in terms of tender joint counts and duration of morning stiffness 
(Fortin et al., 1995). Besides reducing the production of pro-inflammatory eicosanoids 
from n-6 PUFAs, n-3 PUFAs were also found to be effective in inhibiting the synthesis 
of pro-inflammatory cytokines. DHA and ALA-enriched diet can reduce the mRNA 
expression of IL-ȕ,/-6 in pancreas in a cerulein-induced pancreatitis model (Park et 
al., 2009). Fat-1 transgenic mice have a much lower n-6/n-3 fatty acid ratio in tissues 
because the mice are genetically modified to possess the ability to convert n-6 PUFAs to 
n-3 PUFAs (Kang, 2007). In dextran sodium sulfate-induced colitis model, the mRNA 
expression level of TNF in colons was found to be lower in fat-1 mice compared to wild 
type (WT) mice (Hudert et al., 2006).  
40 
 
A number of studies demonstrated the potential protective effects of n-3 PUFAs on 
allergic inflammation in human, especially allergic asthma. In a case-control study 
conducted in Australia, fatty acid intake data including n-6 and n-3 PUFAs were 
collected from 166 asthmatic and 169 normal children (Oddy et al., 2004). The 
difference between asthmatic and control subjects was determined after justifications 
for gender, age, breastfeeding, older siblings, maternal smoking during pregnancy, 
maternal age, maternal asthma, body mass index, total energy intake, and antioxidant 
intake. The logistic regression analysis revealed a positive association between the 
n-6/n-3 fatty acid ratio in diet and risk of asthma (Oddy et al., 2004). Some Northern 
European researchers did a cohort study on the relations between fish intake and asthma, 
which included 16,187 adult subjects aged 23-54 years (Laerum et al., 2007). Multiple 
logistic and cox regression analyses were conducted with adjustment for gender, adult 
hay fever, smoking, age, body mass index, household size, maternal smoking and family 
history of hay fever and asthma. Although no association between childhood fish intake 
and adult asthma was found, an elevated risk of asthma was shown in adults who did not 
consume fish as children (odds ratio=2.03) (Laerum et al., 2007). In a randomized 
placebo-controlled 3-year study (616 children at high risk of asthma enrolled), tuna fish 
oil supplementation significantly reduced the prevalence of cough in atopic children 
(Peat et al., 2004). This suggests that n-3 PUFAs may be effective in preventing the 
development of asthma in early childhood. In another double-blind human study, 
5-weeks of n-3 PUFA-enriched fat blend (contains EPA, DHA, stearidonic acid (n-3) 
DQGȖ-linoleic acid (n-6)) supplementation was reported to significantly decrease exhaled 
NO from young (22-29 years old) asthma patients challenged with low-dose dust mite 
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allergen, which caused the forced expiratory volume in 1 second to decreased by less 
than 5%. Blood eosinophil count and eosinophilic cationic protein were suppressed. The 
mite antigen-induced production of cysteinyl LTs (cys-LTs) by isolated leukocytes from 
these patients was also reduced (Schubert et al., 2009). These results indicate that the 
anti-allergic effect of n-3 PUFAs might be dependent on how n-3 PUFAs are provided in 
terms of dose, what specific kind of n-3 PUFAs were chosen, the age of subjects and the 
severity of disease. However, the association of n-3 PUFAs and reduced allergic 
inflammation seems to be clear, especially before the onset of diseases. Inhibited 
production of AA metabolites (cys-LTs) was suggested to be involved in protective 
effects of n-3 PUFAs on allergic inflammation (Schubert et al., 2009). Since mast cells 
are important effector cells in allergic inflammation that produce AA metabolites and 
mediate the early and late-phase reactions, n-3 PUFAs may down-regulate allergic 
inflammation by inhibiting mast cell activation. 
1.4.4 n-3 PUFAs and mast cells 
The suppressing effect of n-3 PUFAs on mast cell mediator release was indicated in 
some in vitro studies. EPA supplementation was reported to reduce PGD2 production in 
mast cells derived from human umbilical cord mononuclear cells after IgE/anti-IgE 
challenge (Obata et al., 1999). Different types of n-3 PUFAs were also supplemented to 
animal mast cells to test their effect on cell responses. DHA was shown to inhibit PGE2 
production in C2 mast cells activated with the wasp venom peptide mastoparan (Gueck 
et al., 2004). ALA was reported to decrease tryptase activity, PGE2 production, and 
histamine release from C2 cells activated in the same way (Gueck et al., 2004; Gueck et 
al., 2003). In the rat basophilic leukemia cell line RBL-2H3, ALA was shown to 
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decrease histamine release from cells activated with antigen and calcium 
ionophore A23187 (Kawasaki et al., 1994). However, the effect of n-3 PUFAs on 
mediator release from activated mast cells is still under debate because there are some 
issues on the analogy of the mast cell models and the different ways the cells were 
activated in studies introduced above. RBL-2H3 cells have a different membrane 
molecule profile from primary mast cells, and are considered to be closer to basophils 
(Passante et al., 2009). C2 cells may not express functional IgE receptors (Brazis et al., 
2002). Mastoparan and A23187 activate mast cells by G protein activation and 
artificially increasing intracellular calcium levels, respectively. Both of these 
mechanisms are different WR WKH )Fİ5,-mediated pathway, the principle pathway for 
mast cell activation (Siraganian, 2003). There are also studies with the opposite results 
showing that n-3 PUFAs potentiate mast cell mediator release, possibly due to model 
selection and the lack of controls over absorbed amount and the length of fatty acid 
treatment. For example, in RBL-2H3 cells, EPA dissolved in ethanol increased 
degranulation, TNF production, and Syk phosphorylation upon IgE/antigen stimulation 
after 48 hours (hr) treatment, in comparison to untreated cells (Nakano et al., 2005). 
However, RBL-2H3 cells are not a good model to study )Fİ5, signaling because the 
expression of )Fİ5,is not consistent in different labs using the same culture protocol 
(Froese et al., 1982).  
The studies described above provided some indications that n-3 PUFAs may alter 
)Fİ5I-mediated mast cell activation because )Fİ5,signaling shares some down-stream 
signaling cascades with the pathways investigated by these studies, such as calcium 
mobilization (Fig. 1.3) induced by A23187, a calcium ionophore. However, the 
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previous studies presented little information on the mechanisms of how n-3 PUFAs 
regulate mast cell function. Thus, to evaluate the role and mechanisms of n-3 PUFAs in 
PDVWFHOODFWLYDWLRQDVWXG\XVLQJJRRGPDVWFHOODQDORJXHVDFWLYDWHGWKURXJK)Fİ5,LV
needed.  
1.4.5 n-3 PUFAs model systems 
1.4.5.1 In vitro culture systems 
N -3 PUFAs can be supplemented to cell culture as either PUFA sodium salts or 
pure PUFAs dissolved in organic solvent. N-3 PUFA sodium salt is water-soluble which 
is more convenient for dissolving in cell media. PUFAs can be liberated by hydrolysis. 
PUFA sodium salt supplementation can successfully result in PUFA incorporation into 
cells and cell membranes, which has been confirmed by previous study (Corsetto et al., 
2011). PUFA sodium salts dissolved in water are generally stable for up to one year, 
considerably longer than pure PUFAs dissolved in dimethyl sulfoxide (DMSO) (6 
months). Pure n-3 PUFAs are hydrophobic, requiring an organic solvent, such as 
DMSO, to be dissolved. The influence of DMSO on cell function also has to be 
considered, requiring additional controls.  
The primary advantage of in vitro experiments is that the researchers can focus on 
the specific factor in which they are interested, while controlling other factors. In vitro 
studies are also generally less expensive and less time-consuming compared to in vivo 
studies. However, the results of in vitro studies are generated using isolated cells or a 
specific part of tissue/organ of the organism under highly controlled conditions. It is 
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always an issue to translate in vitro results to the biology of the intact organism and 
sometimes it is very easy to over-interpret the in vitro results.  
1.4.5.2 In vivo animal model systems 
n-3 PUFAs could be provided to animals either by food intake or intragastric 
administration. Dietary intervention is the natural way to take in n-3 PUFAs, but it is 
hard to control the amount of food an animal consumes. In addition, some confounding 
factors exist, including consistency of food preparation, food storage conditions, and 
feeding time and duration. It is much easier to control dose using intragastric 
administration. However, the damage to the esophagus is hard to avoid during studies, 
causing loss of appetite and potentially resulting in huge variation in some parameters at 
the end of the study.  
Results from in vivo studies reflect the real circumstances in intact organisms. But, 
it is influenced by numerous factors which cannot be readily controlled. In addition, the 
end point of the study usually means sacrificing the animal, resulting in ethical 
considerations. 
1.4.5.3 The fat-1 mouse model 
Mammals normally cannot produce n-3 PUFAs de novo. The fat-1 transgenic 
mouse is genetically modified to express caenorhabditis elegans fat-1 gene encoding an 
n-3 fatty acid desaturase, which converts n-6 to n-3 PUFAs (Fig. 1.8) (Kang et al., 2004). 
The fatty acid profile data from fat-1 mice demonstrates significantly higher levels of 
n-3 PUFAs and lower levels of n-6 PUFAs than WT in many tissues including muscle, 
heart, brain, liver, kidney, lung, spleen, and even milk (Kang et al., 2004).   
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The fat-1 transgenic mouse has proven to be a model with unique merits (Kang et 
al., 2004). First, fat-1 mice have a reduced n-6/n-3 PUFA ratio with increased n-3 PUFA 
levels and decreased n-6 PUFA levels in tissue, which is greatly desirable for studying 
the effect of the n-6/n-3 PUFA ratio on health. Second, there is no need to prepare 
different diets for the different experimental groups, thus diminishing many confounding 
factors that could occur in a diet intervention study, as described above, and would lead 
to more reliable and definitive results. Third, fat-1 mice can be easily crossed with other 
disease models, including allergic asthma model (Bilal et al., 2011; Lu et al., 2008). The 
main disadvantage of fat-1 model is that gene knockin might result in unpredicted 
changes in phenotype.  
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Figure 1.8 The fat-1 transgenic mouse model. Mammals cannot produce n-3 PUFAs 
de novo. While caenorhabditis elegans can convert n-6 PUFAs to n-3 PUFAs with an 
n-3 fatty acid desaturase encoded by fat-1 gene from Caenorhabditis elegans. 
Introducing of fat-1 gene to mice can enable the animal to produce n-3 PUFAs from n-6 
PUFAs endogenously. PUFAs: Polyunsaturated fatty acids.  
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1.5 Rationale 
n-3 PUFAs have beneficial effects against allergic inflammation. As a vital effector 
cell in allergic inflammation, mast cells are principally activated by IgE-binding antigen 
WKURXJK )Fİ5, ZKLFK LV EHOLHYHG WR RFFXU LQ OLSLG UDIWV IRUPHG E\ KLJK OHYHOV RI
cholesterol, sphingolipids, phospholipids, and proteins. In a C2 canine mastocytoma cell 
line, n-3 PUFA supplementation increased n-3 PUFA levels in both raft and non-raft 
regions, but cholesterol levels did not change (Basiouni et al., 2012), indicating n-3 
PUFA may regulate membrane structure and function. Thus, n-3 PUFAs may change the 
lipid profile of lipid rafts, affect lipid raft property, and disrupt signaling events 
GHSHQGHQWRQOLSLGUDIWVVXFKDV)Fİ5,-mediated signal transduction. The expression of 
some signaling molecules may also be altered by n-3 PUFA through binding to the free 
fatty acid receptors or PPARs (Calder, 2010). 
1.6 General Hypothesis  
n-3 PUFAs inhibit )Fİ5,-mediated signal transduction and mediator release in 
mast cells by LQKLELWLQJWKHH[SUHVVLRQRIVRPHPROHFXOHVLQYROYHGLQ)Fİ5,VLJQDOLQJ
and physically disrupting receptor association with lipid rafts.  
1.7 Objectives 
To determine the effect of both exogenous and endogenous n-3 PUFAs on 
)Fİ5,-mediated mast cell activation, two types of cells were used, mouse bone 
marrow-derived mast cells (BMMC) and laboratory of allergic diseases 2 
(LAD2) human mast cells. BMMC are mucosal-type mast cells expressing functional 
)Fİ5,DQGNLWRQFHOOVXUIDFHV%LVFKRII7KHy are IL-3 dependent and produce all 
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three groups of mediators under IgE/antigen challenge. BMMC are long lasting and the 
high yield could be easily achieved (Bischoff, 2007). LAD2 cells are connective-tissue 
mast cells that are dependent on SCF. They also H[SUHVVIXQFWLRQDOFHOOVXUIDFH)Fİ5,
(Bischoff, 2007). Increased n-3 PUFA levels were achieved in two ways. BMMC were 
cultivated from fat-1 transgenic mice which can produce n-3 PUFAs endogenously 
(section 1.4.5.3). Exogenously, n-3 PUFA sodium salts were supplemented to WT 
BMMC and LAD2 cells. The specific objectives of this project are to: 
1) Characterize the effects of long chain n-3 PUFAs on )Fİ5,-mediated mast cell 
mediator release. 
We hypothesized that n-3 PUFAs inhibit )Fİ5,-mediated mast cell activation. The 
fatty acid profile in mast cells will be measured by gas chromatography-mass 
spectrometry (GC-MS) to determine if the fatty acid profile is changed in fat-1 BMMC 
and long chain n-3 PUFA-supplemented BMMC )Fİ5,-mediated mast cell 
degranulation, cys-LTs release, and cytokine/chemokine production will be measured 
by ȕ-KH[RVDPLQLGDVH ȕ-hex) release assay and enzyme-linked immunosorbent assay 
(ELISA) to determine if long chain n-3 PUFAs modulate mediator release of mast cells 
activated through )Fİ5,  
2) Examine the effects of long chain n- 38)$V RQ )Fİ5, H[SUHVVLRQ DQG
association with lipid rafts, )Fİ5,-mediated signal transduction, and expression of 
signaling proteins. 
We hypothesized that long chain n-3 PUFAs suppress )Fİ5,-mediated signal 
transduction, disrupt )Fİ5,DVVRFLDWLRQZLWKOLSLGUDIWVLQUHVWLQJDQGDFWLYDWHGPDVW
cells, and inhibit expression of some signaling proteins. Lipid rafts will be isolated by 
49 
 
sucrose gradient centrifugation for further protein and lipid analysis. The expressions 
RI)Fİ5,RQWKHFHOOVXUIDFH, in whole cell lysates, and in lipid rafts will be measured by 
flow cytometry and western blot analysis to determine whether long chain n-3 PUFAs 
influence )Fİ5, expression on cell surface, in whole cell, and in lipid rafts. GC-MS 
will be used to determine if the fatty acid profile of the lipid rafts is altered in fat-1 
BMMC. The expression and phosphorylation of Lyn, Syk, LAT after IgE/antigen 
stimulation will be measured by western blot analysis to see if long chain n-3 PUFAs 
modulate )Fİ5,-mediated signal transduction and expression of signaling proteins.  
3)  Evaluate the effects of lipid raft disruption on )Fİ5,-mediated activation of 
both WT and long chain n-3 PUFA-enriched mast cells.  
We hypothesized that mast cell activation is diminished by lipid raft disruption in 
both WT and long chain n-3 PUFA-enriched mast cells. Lipid rafts of WT and fat-1 
BMMC will be disrupted by depleting cholesterol with MBCD. Mast cell degranulation, 
cys-LT release and cytokine/chemokine production will be measured to determine the 
effect of lipid raft disruption on FcİRI-mediated activation of WT and fat-1 BMMC.  
The measurement of mediator release represents mast cell activation. The results 
of flow cytometry and western blot analysis offer evidence to determine the effect of 
long chain n-3 PUFAs on )Fİ5, expression on cell surface, in whole cell lysates and 
rafts of resting cells, and the influence of long chain n-3 PUFAs on Fcİ5, shuttling in 
lipid rafts of activated cells and the expression and phosphorylation of signaling 
proteins. GC-MS analysis enables the evaluation of whether long chain n-3 PUFAs 
alter fatty acid composition of whole cells and rafts. This study could provide evidence 
on whether and how long chain n-3 PUFAs influence )Fİ5,-mediated mast cell 
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activation. This study could also clarify how exactly )Fİ5, mobilize in lipid rafts of 
mast cells, and the effect of long chain n-3 PUFAs on )Fİ5, localization and 
mobilization in lipid rafts of mast cells.  
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MODULATE MAST CELL MEDIATOR RELEASE AND 
FATTY ACID PROFILE 
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2.1 Abstract 
Aim of the study: The consumption of long chain n-3 polyunsaturated fatty acids (PUFAs) 
has been associated with reduced allergic inflammation. We hypothesized that long 
chain n-3 PUFAs inhibit mast cell activation induced through the high affinity 
immunoglobulin E (IgE) receptor, Fc İ receptor I ()Fİ5,). 
Methodology: Bone marrow-derived mast cells (BMMC) and laboratory of allergic 
diseases 2 (LAD2) cultured human mast cells were supplemented with eicosapentaenoic 
acid (EPA, n-3), docosahexaenoic acid (DHA, n-3) and arachidonic acid (AA, n-6). 
Fat-1 transgenic BMMC were cultured from bone marrow of fat-1 transgenic mice. Gas 
chromatography-mass spectrometry (GC-MS) was used to evaluate lipid profiles. 
ȕ-KH[RVDPLQLGDVHȕ-hex) release, cysteinyl leukotriene (cys-LTs) synthesis, and tumor 
necrosis factor (TNF) and CC chemokine ligand 2 (CCL2) production were measured by 
ELISA after IgE/2,4-dinitrophenyl- Human serum albumin (DNP-HSA) activation. 
Calcium mobilization was measured by fura-2 calcium imaging.  
Results: Long chain n-3 PUFA levels were increased in fat-1 BMMC and BMMC 
supplemented with EPA and DHA compared to WT. EPA supplementation reduced 
ȕ-hex release in LAD2 cells. /HVVȕ-hex, TNF, CCL2 and cys-LTs were produced by 
fat-%00&ȕ-hex release,cys-LT synthesis and CCL2 production were also decreased 
in EPA-treated BMMC. DHA supplementatioQFDXVHGȕ-hex release and TNF, CCL2 
production to decrease in BMMC ȕ-hex release from BMMC was also reduced in 
AA-treated cells. Calcium mobilization was decreased in fat-1 BMMC after cell 
activation.  
Conclusion: Long chain n-3 PUFAs inhibit )Fİ5,-mediated mast cell mediator release. 
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2.2 Introduction 
n-3 polyunsaturated fatty acids (PUFAs) are a subgroup of fatty acids containing 
more than one double bond with the first double bond located between the third and 
fourth carbons from the methyl end (Fig. 1.6)Į-Linolenic acid (ALA) is the precursor of 
other n-3 PUFAs, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), the main active forms of n-3 PUFAs in the human body. EPA and DHA can be 
derived from ALA by enzyme-FDWDO\]HGHORQJDWLRQGHVDWXUDWLRQDQGȕ-oxidation (Fig. 
1.7). Long chain n-3 PUFAs have a broad range of health benefits in humans. It is well 
established that diets rich in n-3 PUFAs are associated with lower risks of cancer, 
cardiovascular disease, neurodegenerative disease, hyperlipidemia, and hypertension 
(Abeywardena and Patten, 2011; Finocchiaro et al., 2012; Liu et al., 2011; Puri et al., 
2005; Skulas-Ray et al., 2011).  
Recently, the association between long chain n-3 PUFAs and allergic inflammation 
has been demonstrated in allergic asthma patients. For example, the dietary n-6/n-3 
PUFA ratio is positively correlated with risk for asthma in children (Oddy et al., 2004), 
and long chain n-3 PUFA supplementation is protective against asthma in both asthmatic 
patients and in vivo animal asthma models (Schubert et al., 2009; Yokoyama et al., 
2000). The ability of long chain n-3 PUFAs to inhibit some of the symptoms associated 
with asthma has been attributed to decreased 4-series leukotriene (LT) and increased 
5-series LT production by activated leukocytes (Schubert et al., 2009), decreased 
eosinophil and neutrophil infiltration in bronchoalveolar lavage fluid (BALF) 
(Yokoyama et al., 2000), decreased production of pro-inflammatory cytokines such as 
interleukin (IL)-Į ,/-5, IL-9, IL-13, tumor necrosis factor (TNF), granulocyte/ 
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macrophage colony-stimulating factor (GM-CSF), CC chemokine ligand 5 (CCL5) in 
BALF, and increased expression of protectin D1 and resolvin E1 in the lungs (Bilal et 
al., 2011). Mast cells are known to be key effector cells that mediate allergic 
inflammatory responses (Theoharides and Kalogeromitros, 2006). The connection 
between long chain n-3 PUFAs and reduced mast cell activation was suggested by some 
studies. For example, EPA was reported to inhibit prostaglandin (PG) D2 production by 
mast cells activated by immunoglobulin E (IgE)/anti-IgE (Obata et al., 1999). However, 
the effect of long chain n-3 PUFAs on mast cell activation is still poorly understood.  
Mast cells can be activated by allergens, complements, antimicrobial peptides, 
adenosine, neuropeptides and physical stimuli (Galli et al., 2005). The principle 
allergen-induced activation pathway is mediated by the high affinity IgE receptors, Fc İ 
UHFHSWRU,)Fİ5,(Gilfillan and Tkaczyk, 2006))Fİ5,W\SLFDOO\KDVDKHWHURWHWUDPHULF
VWUXFWXUH ĮȕȖ FRPSRVHG RI RQH Į VXEXQLW ZLWK DQ H[WUDFHOOXODU GRPDLQ IRU ,J(
binding, a four-transmembrane-VSDQQLQJȕVXEXQLWDQGWZRLGHQWLFDOGLVXOSKLGHOLQNHGȖ
subunits (Kraft and Kinet, 2007) as shown in Fig. 1.1. The cross-linking of IgE-bound 
)Fİ5, E\ DQWLJHQ OHDGV WR PDVW FHOO GHJUDQXODWLRQ UHVXOWLQJ LQ UHOHDVH RI SUHIRUPHG
mediators such as histamine, synthesis of lipid-derived mediators such as LTs and PGs, 
and cytokine/chemokine production (Hofmann and Abraham, 2009).  
In this study, I hypothesized that long chain n-3 PUFAs can inhibit mast cell 
mediator release induced by IgE/antigen. Long chain n-3 PUFAs were supplemented to 
mouse and human mast cells. I also cultivated bone marrow-derived mast cells (BMMC) 
from fat-1 transgenic mice which have elevated long chain n-3 PUFA levels compared to 
wild type (WT) mice. The fat-1 gene encodes a fatty acid n-3 desaturase from C. elegans 
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and allows fat-1 transgenic mouse to convert n-6 to n-3 PUFAs, resulting in endogenous 
conversion of n-6 PUFAs to n-3 PUFAs (Kang et al., 2004) (Fig. 1.8). In wild type (WT) 
mice (as with all mammals), n-3 PUFAs cannot be synthesized de novo; they must be 
consumed through diet. The effects of long chain n-3 PUFAs on mast cell activation 
were evaluated in the context of degranulation, cysteinyl leukotriene (cys-LT) release, 
and cytokine/chemokine production.    
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2.3 Materials and Methods 
2.3.1 Animals and diet 
The femurs of WT and fat-1 mice were provided by Dr. David W.L. Ma, University 
of Guelph (Guelph, ON). With the approval from the University of Guelph Animal Care 
Committee, fat-1 mice were obtained by breeding C57BL/6 × C3H fat-1 males 
(provided by Dr. Jing X. Kang, Harvard Medical School, Boston, MA) with wild type 
(WT) C57BL/6 females (Charles River, Saint-Constant, QC). WT and fat-1 mice were 
all housed in standard clean environmental conditions with controlled temperature and 
humidity. An AIN-93G diet supplemented with 10% linoleic acid-enriched safflower oil 
(Research Diets, New Brunswick, NJ) was provided ad libitum to all animals.  
2.3.2 Growth of human and mouse mast cells 
Laboratory of allergic diseases 2 (LAD2) human mast cells were cultured in 
StemPro-34 SFM media (Life Technologies, Burlington, ON) supplemented with 2 mm 
L-glutamine (Corning cellJUR 0DQDVVDV 9$  8P/ SHQLFLOOLQ ȝJP/
streptomycin (Corning cellgro) and 100 ng/mL stem cell factor (Life Technologies). 
Cells were fed every 4-5 days.  
 BMMC were cultivated from the bone marrow of WT and fat-1 transgenic mice. 
Cells were maintained in RPMI-1640 media (Corning cellgro) supplemented with 4 mM 
L-JOXWDPLQH&RUQLQJFHOOJURȝ0%0(6LJPD-Aldrich, Oakville, ON), 1 mM Na 
S\UXYDWH &RUQLQJ FHOOJUR  8P/ SHQLFLOOLQ ȝJP/ VWUHSWRP\FLQ &RUQLQJ
cellgro), 0.1 mM nonessential amino acids (Corning cellgro), 25 mM HEPES (Corning 
cellgro), 10% FBS (Gibco, Burlington, ON) and 10 ng/mL mouse recombinant 
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interleukin (IL)-3 (BioLegend, San Diego, CA). Cells were fed every 3-5 days. After 4 to 
5 weeks, cell purity was determined by measuring expression of cluster of differentiation 
(CD)117 (c-KitDQG)Fİ5,E\IORZF\WRPHWU\$IWHUZHHNVRIWKHFHOOVZHUH
GRXEOHSRVLWLYH IRU&'DQG)Fİ5, The cell viability was monitored using trypan 
blue staining (Sigma-Aldrich). 
2.3.3 Toluidine blue staining 
Slides were prepared using Shandon Cytospin Cytocentrifuge (Thermo Fisher 
Scientific Inc, Waltham, MA) with 1×105 cells. Cells on the slide were then fixed with 
0RWD¶VIL[DWLYHFRQWDLQLQJOHDGDFHWDWHEDVLF6LJPD-Aldrich) for 15 minutes (min). 
After washing and drying, cells were stained with 0.5% toluidine blue (Sigma-Aldrich) 
for 20 min.  
2.3.4 Flow cytometry 
Briefly, cells were washed with phosphate-buffered saline (PBS) containing 0.1% 
BSA (Sigma-Aldrich) and re-suspended in PBS containing 1.55% BSA (2× 106 
FHOOVP/DQGWKHQLQFXEDWHGLQȝJP/rat anti-mouse CD117 (c-Kit) phycoerythrin 
(PE)-&\ H%LRVFLHQFH 6DQ 'LHJR &$ DQG  ȝJP/ armenian hamster anti-mouse 
)Fİ5,Į3(H%LRVFLHQFHIRUhour (hr). After washing twice with 0.1% BSA in PBS, 
cells were re-VXVSHQGHGLQȝO%6$LQ3%6DQGWUDQVIHUUHGWRDURXQGERWWRP
96-well plate. Cell samples were analyzed on a FACS Array flow cytometer (BD 
Biosciences, Mississauga, ON).  Rat IgG2bK PE-Cy7 (eBioscience) and armenian 
hamster IgG PE (eBioscience) were used as isotype controls. Data was generated using 
WinMDI 2.9 software. 
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2.3.5 Fatty acid supplementation to BMMC and LAD2 cells 
LAD2 cells were supplemented with 0.1, 1, 10, 100 and 500 µM EPA-Na, 
DHA-Na, or arachidonic acid (AA)-Na for 24 hr and 48 hr at 5× 105 cells/mL. WT 
BMMC were spun down and resuspended in fresh media at 5× 105 cells/mL. EPA-Na 
(Sigma-Aldrich), DHA-Na (Sigma-Aldrich), or AA-Na (Sigma-Aldrich) in PBS was 
supplemented to cell cultures for 24 hr in a final concentration of 100 µM, as indicated 
by the results gained in LAD2 cells.  
2.3.6 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT) assay 
After fatty acid supplementation to BMMC and LAD2 cells, cell viability was 
measured using a XTT proliferation kit (Roche Molecular Biochemicals, Indianapolis, 
IN) according to the instructions from the manufacturer.  
2.3.7 RNA isolation, cDNA synthesis, and reverse transcription polymerase chain 
reaction (RT-PCR) 
Total RNA was isolated from BMMC using TRI reagent (Sigma-Aldrich). First 
VWUDQGF'1$ZDVJHQHUDWHG IURPȝJ51$ with the mixture of 200 units Moloney 
PXULQHOHXNHPLDYLUXVUHYHUVHWUDQVFULSWDVH/LIH7HFKQRORJLHVȝJP/ROLJRG7
primer (Promega, Madison, WI), 10 mM dNTP Mix (Promega), 0.1 M DTT (Life 
Technologies), and 5× first strand buffer (Life Technologies).  
RT-3&5ZDVSHUIRUPHGZLWKȝORIF'1$UHDFWLRQPL[HGZLWK[3&5%XIIHU
(Life Technologies), 50 mM MgCl2 (Life Technologies), 10 mM dNTP mix (Life 
Technologies), 5 U/µL Taq DNA polymerase (Life Technologies), forward primer 
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ƍ-TGTTCATGCCTTCTTCTTTTTCC-ƍ DQG  UHYHUVH SULPHU
ƍ-GCGACCATACCTCAAACTTGGA-ƍ IRU WKH fat-1 transgene; forward primer 
ƍ-GTGTTCCTACCCCCAATGTG-ƍ DQG UHYHUVH SULPHU
ƍ-GGTCCTCAGTGTAGCCCAAG-ƍ IRU JO\FHUDOGHK\GHV -phosphate 
dehydrogenase (GAPDH) using MyCycler Thermal Cycler (Bio-Rad Laboratories, 
Hercules, CA) at the following cycling program: 94°C for 2 min (1 cycle); 94°C for 30 s, 
51°C for 30 s, 72°C for 30 s (35 cycles); and 72°C for 7 min (1 cycle). The PCR products 
were analyzed with 1.5% agarose electrophoresis, followed by exposing gel to 
ultraviolet (UV) light in a ChemiDoc XRS system (BD Biosciences) for image 
acquisition.  
2.3.8 Gas chromatography±mass spectrometry (GC-MS)   
Lipid was extracted and methylated by the method modified from a previous study 
(Kang and Wang, 2005). Briefly, 6× 106 BMMC were mixed with 1 mL hexane and 1 
mL 14% BF3/MeOH. After blanketing with nitrogen, samples were heated at 100°C for 
1 hr. One milliliter H2O was added prior to centrifugation at 200× g for 1 min. The upper 
hexane layer containing fatty acid methyl esters (FAMEs) was collected for GC-MS 
analysis. 
GC-MS was performed in an Agilent 6890N network GC system (Agilent 
Technologies, Mississauga, ON) with a split/splitness injector (Agilent Technologies) 
(Agilent Technologies). Fatty acid components were detected by a flame ionization 
detector (Agilent Technologies) and a MS detector (Agilent Technologies). A supelco 
37 component FAME mix standard (Sigma-Aldrich) was used to check the performance 
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of the GC instrument. Samples were analyzed using DB-23 column (Agilent 
Technologies) with helium as the carrier gas at a flow rate of 1.0 ml/min. 
2.3.9 Degranulation assay 
BMMC were first incubated with 500 ng/mL mouse anti-2,4-dinitrophenyl (DNP) 
IgE (Sigma-Aldrich) at 5× 105 cells/mL in complete media for 24 hr for sensitization. 
Cells were then re-suspended in HEPES buffer (10 mM HEPES, 137 mM NaCl, 2.7 mM 
KCl, 0.4 mM Na2HPO4ǜ+2O, 5.6 mM glucose, 1.8 mM CaCl2ǜ+2O, 1.3 mM 
MgSO4ǜ+2O) and transferred to a round bottom 96-well plate. Finally, cells were 
treated with DNP-human serum albumin (DNP-HSA, Sigma-Aldrich) in varying 
concentrations of 0.001, 0.01, 0.1, 1, 10, 100, 200, 500 ng/mL for 30 min for stimulation. 
LAD2 cells were sensitized with 500 ng/mL IgE-biotin (BioLegend) for 24 hr, followed 
by stimulation with 500 ng/mL streptavidin (Sigma-Aldrich) for 30 min.   
After sensitization and stimulation, mast cell degranulation was assessed by 
PHDVXULQJȕ-hexosaminidase (ȕ-hex) release. Briefly, each cell suspension was spun at 
200× g for 5 min, and the supernatant and pellet fraction were separated. Fifty microliter 
RI VXSHUQDWDQW ZDV LQFXEDWHG ZLWK  P0 ȕ-hex substrate 4-nitrophenyl 
N-acetyl-ȕ-D-glucosaminide (Sigma-Aldrich) in 0.04 M citrate buffer (pH 4.5) at 37°C 
for 1.5 hr. Fifty microliter of the pellet fraction was suspended with 0.1% Triton X-100 
for 2 min at room temperature, and then incubated with 1 mM 4-nitrophenyl 
N-acetyl-ȕ-D-glucosaminide at 37°C IRU  KU $IWHU DGGLQJ  ȝO  0 JO\FLQH
(pH10.7) to both supernatant and pellet plates, absorbance was measured at A405 and 
A570 in a Multiskan Ascent 354 microplate reader (Thermo LabSystems, Vantaa, 
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Finland). Data was generated by using the following formula: % release = 100 × 
supernatant absorbance/(0.5 × supernatant absorbance + pellet absorbance).   
2.3.10 Enzyme-linked immunosorbent assay (ELISA) for cys-LTs, TNF, and CC 
chemokine ligand 2 (CCL2) 
BMMC were first sensitized for 24 hr with 500 ng/mL mouse anti-DNP IgE 
(Sigma-Aldrich). The cell suspension was transferred to a 6-well plate. After stimulating 
cells with DNP-HSA (Sigma-Aldrich) in varying concentrations of 1, 10, 100, 200, 500 
ng/mL for 6 hr at 37°C for cytokine/chemokine production or 3 hr at 37°C for cys-LT 
release, supernatant was collected for ELISA measurements by centrifuging the cell 
suspension at 200× g for 5 min. 
The supernatant was analyzed for TNF, CCL2, and cys-LT release using 
commercial ELISA kits (eBioscience; Enzo Life Sciences, Farmingdale, NY) according 
WRWKHPDQXIDFWXUHUV¶SURWRcols.  
2.3.11 Calcium mobilization 
WT and fat-1 BMMC were first sensitized with 500 ng/mL anti-DNP IgE for 24 hr.  
&HOOVZHUHWKHQORDGHGZLWK(?ȝ0IXUD-2 AM (Invitrogen) in HEPES buffer for 30 min in 
the dark. After washing, cells were seeded in a concentration of 3× 106 cells/mL in a 
glass-bottomed culture dish coated with 10 mg/mL poly-D-lysine (Sigma-Aldrich) 
overnight. The calcium response was recorded using an inverted microscope (IX71, 
Olympus Canada Inc., Toronto, ON). Fura-2 was excited at 340 and (?QPExcitation 
of calcium-bound fura-2 at 340 nm leads to increased fluorescence emission. In contrast, 
excitation of fura-2 at 380 nm leads to decreased fluorescence emission. So the ratio of 
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fluorescence emission 340/380 indicates calcium concentration, and the influence of 
difference in fura-2 concentration and cell thickness are ruled out. DNP-HSA was added 
DW WKH WLPHSRLQWRI(?V in concentration of 10 ng/mL. The response of 20 randomly 
selected cells was analyzed using SlideBook 4.0 software (Olympus).  
2.3.12 Statistical analysis 
The differences of fatty acid profile between WT and fat-1 BMMC, and between 
groups of PUFA-treated BMMC were determined using Student's t-test and one-way 
analysis of variance (ANOVA) followed by the post-hoc Bonferroni test. Two-way 
ANOVA followed by the post-hoc Bonferroni test was used to evaluate the differences 
in mediator release between WT and fat-1 BMMC, and among PUFA-treated BMMC. 
Statistical significance was set at p<0.05. Statistical analysis was performed using SPSS 
11.5 statistical software package (IBM Corporation, Armonk, NY).   
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2.4 Results 
2.4.1 BMMC and LAD2 genotyping and phenotyping 
Toluidine blue stained BMMC and LAD2 cells were round and nuclei were big with 
clear boundaries. Granules were clearer in the cytoplasm of BMMC and LAD2 cells 
(Figs. 2.1 and 2.2). After 4 weeks of culture, more than 99% of BMMC were double 
positive for the mast cell markers CD117 and )Fİ5, (Fig. 2.3).  
 
 
 
 
 
 
 
 
 
 
 
83 
 
 
 
Figure 2.1 Toluidine blue staining of BMMC (100 × magnification) 
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Figure 2.2 Toluidine blue staining of LAD2 cells (100 × magnifications) 
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2.4.2 The effect of long chain n-3 PUFA supplementation on mast cell viability 
The XTT assay showed that 24 hr and 48 hr treatments of 0.1, 1, 10, 100 µM 
EPA-Na, DHA-Na, AA-Na did not influence LAD2 cell viability. However, 500 µM 
EPA-Na, DHA-Na, AA-Na supplementation for 24 hr and 48 hr all significantly reduced 
LAD2 cell viability by >50% (all, p<0.001, Fig. 2.4). After 24 hr, 100 µM of EPA-Na, 
DHA-Na, and AA-Na supplementation was not cytotoxic to BMMC (Fig. 2.5).  
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Figure 2.5 The effect of long chain PUFA supplementation on cell viability of 
BMMC. BMMC were treated with 100 µM EPA-Na, DHA-Na, and AA-Na for 24 hr. 
Cell viability was measured by XTT assay and is compared to untreated controls. Error 
bars represent SEM (n=3). XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)- 
2H-tetrazolium-5- carboxanilide. 
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2.4.3 The effect of long chain n-3 PUFA supplementation on n-3 PUFA levels of 
BMMC  
 EPA-Na treatment increased EPA level (p=0.004) and docosapentaenoic acid 
(DPA) level (p=0.007) of BMMC. DHA-Na treatment increased DHA level (p=0.044). 
AA-Na treatment increased AA level (p=0.001) (Figs. 2.6-2.9, Table 2.1). Compared to 
untreated cells, significant lower n-6/n-3 ratios were seen in EPA-Na (p=0.034) and 
DHA-Na (p=0.027) treatments. AA-Na supplementation resulted in a much higher 
n-6/n-3 ratio (p<0.001) than untreated cells. 
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Table 2.1 Fatty acid composition of long chain PUFA-supplemented WT BMMC  
Fatty acids 
Percentage of total fatty acids (%) 
Control  EPA-Na DHA-Na AA-Na 
16:0  15.94 ± 5.65  17.35 ± 6.10 13.44 ± 5.89 14.98 ± 4.68 
18:0  25.24 ± 4.41  26.70 ± 2.13 38.12 ± 3.06 24.01 ± 1.17 
18:1 n-9  21.16 ± 4.94  14.89 ± 4.50 13.07 ± 0.34 12.41 ± 1.37 
18:2 n-6  6.01 ± 1.40 5.34 ± 0.46 3.57 ± 0.87 5.11 ± 0.63 
20:4 n-6 
(AA)  20.83 ± 3.93  16.72 ± 2.03 14.85 ± 2.97 40.26 ± 4.40
**
 
20:5 n-3 
(EPA) 1.00 ± 0.28  6.84 ± 2.56
**
  0.71 ± 0.04 nd 
22:5 n-3 
(DPA)  2.57 ± 1.15  9.52 ± 2.13
**
  1.34 ± 0.86 1.25 ± 0.61 
22:6 n-3 
(DHA)  7.25 ± 1.25  2.65 ± 1.18 14.91 ± 5.10*  1.99 ± 3.03 
n-6/n-3 
ratio  2.48 ± 0.08  1.16 ± 0.80
*
  1.09 ± 0.19*  12.39 ± 0.78** 
Values are mean ± SEM, n=3.  
*: p<0.05, compared with control group, one-way ANOVA followed by the post-hoc Bonferroni test 
**: p<0.01, compared with control group, one-way ANOVA followed by the post-hoc Bonferroni test 
AA: Arachidonic acid; DHA: Docosahexaenoic acid; DPA: Docosapentaenoic acid; EPA: 
Eicosapentaenoic acid; nd: not detected. 
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2.4.4 The effect of long chain n-3 PUFA supplementation on mast cell 
degranulation 
EPA-Na supplementation for 24 hr and 48 hr decreased LAD2 degranulation by 
30.5% and 35.3% compared to untreated cells (stimulated with 500 ng/mL streptavidin 
for 30 min) (p=0.001 and p<0.001). DHA-Na treatment had no effect on LAD2 cell 
degranulation. AA-Na 24 hr supplementation also inhibited LAD2 degranulation by 
55.5% and 56% (p<0.001 and p<0.001) (Fig. 2.10). EPA-Na and DHA-Na 24 hr 
treatment GHFUHDVHG %00& ȕ-hex release activated by DNP-HSA in concentration 
range of 1-500 ng/mL. In response to 200 ng/mL stimulation, EPA-Na, and DHA-Na 
VXSSOHPHQWDWLRQ UHGXFHG ȕ-hex release by 45.2 % (p=0.002) and 45.7% (p=0.007) 
compared to untreated cells. AA-1DVXSSOHPHQWDWLRQLQFUHDVHGȕ-hex release by 58.1% 
(p=0.004) by cells activated with 1 ng/mL DNP-HSA, and inhibited ȕ-hex release by 
cells activated with 100 ng/mL (40.1%, p<0.001) and 200 ng/mL (34.6%, p=0.006) 
DNP-HSA compared to untreated cells (Fig. 2.11).  
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Figure 2.10 IgE/DNP-HSA-induced degranulation of LAD2 cells treated with 100 
µM EPA-Na, DHA-Na, and AA-Na for 24 hr and 48 hr. PUFA-Na-treated cells were 
sensitized with 500 ng/mL IgE-biotin for 24 hr, and then stimulated with 500 ng/mL 
VWUHSWDYLGLQIRUPLQ'HJUDQXODWLRQZDVHYDOXDWHGE\PHDVXULQJȕ-hex release. Error 
bars represent SEM (n=3). *: p<0.01, compared to untreated control (n=3), one-way 
ANOVA followed by the post-hoc Bonferroni test. 
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2.4.5 The effect of long chain n-3 PUFA supplementation on cys-LT release by 
BMMC  
BMMC supplemented with EPA and stimulated with 100 ng/mL DNP-HSA produced 
significantly less cys-LTs (870.4 pg/mL, p=0.007, Fig. 2.12) compared to the untreated 
control (1236.8 pg/mL). BMMC supplemented with AA produced more cys-LTs in response 
to 100 ng/mL DNP-HSA (1623.7 pg/mL, p=0.033) compared to untreated controls (1236.8 
pg/mL) (Fig. 2.12). DHA-Na supplementation had no effect on DNP-HSA-induced cys-LT 
production from BMMC.  
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2.4.6 The effect of long chain n-3 PUFA supplementation on cytokine/chemokine 
production by BMMC 
In response to 10 ng/mL DNP-HSA, BMMC supplemented with DHA-Na showed 
less TNF production (1140.1 pg/mL, p<0.001) compared to untreated cells (1631.4 
pg/mL). DHA supplementation also decreased CCL2 production under 100 ng/mL 
DNP-HSA (315.8 pg/mL, p<0.001) compared to untreated control (437.6 pg/mL). EPA 
supplementation inhibited CCL2 production (317.5 pg/mL, p=0.005) compared to 
untreated controls (437.6 pg/mL) at 100 ng/mL DNP-HSA stimulation. AA 
supplementation increased TNF production under 10 ng/mL (3143.8 pg/mL, p<0.001) 
DNP-HSA stimulation compared to untreated control (1631.4 pg/mL) and decrease 
CCL2 production (320.3 pg/mL, p=0.045) at 100 ng/mL DNP-HSA compared to control 
(437.6 pg/mL) (Fig. 2.13).  
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2.4.7 n-3 PUFA levels in fat-1 BMMC  
As shown in Fig. 2.14, fat-1 mRNA was expressed in fat-1 BMMC, but not in WT 
BMMC. In contrast, the housekeeping gene, GAPDH, was equally expressed in both 
WT and fat-1 BMMC. Among the 8 fatty acids identified with GC-MS (i.e. palmitic acid 
(16:0), stearic acid (18:0), oleic acid (18:1, n-9), linoleic acid (18:2 n-6), AA (20:4 n-6), 
EPA (20:5 n-3), docosapentaenoic acid (DPA, 22:5 n-3), and DHA (22:6 n-3)), fat-1 
BMMC had significantly lower AA (p=0.007) and higher EPA (p=0.005) and DPA 
(p=0.014) levels than WT BMMC (Fig. 2.15 and Table 2.2). The n-6/n-3 ratio of WT 
BMMC was, therefore, significantly higher than that of fat-1 BMMC (6-fold, p<0.001, 
Table 2.2).  
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Figure 2.14 mRNA expression of fat-1 (target gene) and GAPDH (housekeeping 
gene) in WT and fat-1 BMMC. mRNA expression was analyzed by RT-PCR followed 
with 1.5% agarose gel electrophoresis and detection under UV light. WT: Wild type. 
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Table 2.2 Fatty acid composition of WT and fat-1 BMMC  
Fatty acids Percentage of total fatty acids (%) WT BMMC fat-1 BMMC 
16:0  18.69 ± 4.84 18.38 ± 3.29 
18:0  23.42 ± 6.18 22.77 ± 3.08 
18:1 n-9  15.04 ± 4.65 20.08 ± 5.31 
18:2 n-6  4.23 ± 0.75 5.89 ± 0.82 
20:4 n-6 (AA)  24.39 ± 6.62 2.78 ± 0.61**  
20:5 n-3 (EPA)  0.59 ± 0.17 5.05 ± 1.09**  
22:5 n-3 (DPA) 4.56 ± 1.22 11.93 ± 1.35*  
22:6 n-3 (DHA) 9.07 ± 2.76 13.12 ± 2.19 
n-6/n-3 ratio  1.84 ± 0.05  0.32 ± 0.05**  
Values are mean ± SEM, n=3. 
*: p<0.05, compared with WT BMMC, Student's t-test.   
*: p<0.01, compared with WT BMMC, Student's t-test.   
AA: Arachidonic acid; DHA: Docosahexaenoic acid; DPA: Docosapentaenoic acid; EPA: 
Eicosapentaenoic acid; WT: Wild type. 
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2.4.8 Degranulation, lipid-derived mediator release and cytokine/chemokine 
production in fat-1 BMMC  
Compared to WT BMMC, fat-1 %00& KDG ORZHU ȕ-hex release in varying 
concentrations of DNP-HSA and the difference was significant (29.1% compared to 
37.5 % by WT BMMC stimulated with 100 ng/mL DNP-HSA, p<0.001) (Fig. 2.16).  
Fat-1 BMMC produced less cys-LTs under the stimulation by 10 ng/mL DNP-HSA 
(1181.3 pg/mL) and 100 ng/mL DNP-HSA (885.2 pg/mL) compared to WT BMMC 
(1612.7 pg/mL, 10 ng/mL DNP-HSA, p=0.034; 1313.1 pg/mL, 100 ng/mL DNP-HSA, 
p=0.033) (Fig. 2.17).  
Fat-%00&VWLPXODWHGYLD)Fİ5,SURGXFHGOHVV71)FRPSDUHGWR:7%00&
(738 pg/mL compared to 982.8 pg/mL in 10 ng/mL DNP-HSA, p=0.029; 350.7 pg/mL 
compared to 707.8 pg/mL in 200 ng/mL DNP-HSA, p<0.001) (Fig. 2.18A). Similarly, 
fat-1 BMMC produced less CCL2 compared to WT BMMC (1131.3 pg/mL compared to 
1640.2 pg/mL in 10 ng/mL DNP-HSA, p<0.001) (Fig. 2.18B).  
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Figure 2.16 IgE/DNP-HSA-induced degranulation of WT and fat-1 BMMC. Cells 
were sensitized with 500 ng/mL mouse anti-DNP IgE for 24 hr, and then stimulated with 
indicated concentrations of DNP-HSA for 30 min. Degranulation was evaluated by 
PHDVXULQJȕ-hex release. Error bars represent SEM (n=3). *: p<0.05, compared to WT 
BMMC, two-way ANOVA followed by the post-hoc Bonferroni test. WT: Wild type. 
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Figure 2.17 IgE/DNP-HSA-induced cys-LT release by WT and fat-1 BMMC. Cells 
were sensitized with 500 ng/mL mouse anti-DNP IgE for 24 hr, and then stimulated with 
indicated concentrations of DNP-HSA for 3 hr. Cys-LT release was measured by 
ELISA. Error bars represent SEM (n=3). *: p<0.05, compared to WT BMMC, two-way 
ANOVA followed by the post-hoc Bonferroni test. WT: Wild type. 
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2.3.9 Calcium release in fat-1 BMMC 
Calcium imaging on WT and fat-1 BMMC after IgE sensitization and DNP-HSA 
stimulation showed that there was no difference in intracellular calcium levels between 
WT and fat-1 BMMC before activation (Fig. 2.19). However, fat-1 BMMC had lower 
calcium responses (81%) FRPSDUHGWR:7%00&DIWHUFHOODFWLYDWLRQWKURXJK)Fİ5,
(p=0.026). 
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2.5 Discussion 
,QWKLVVWXG\WKH)Fİ5,-mediated mediator release of mast cells was clearly shown 
to be inhibited by either exogenous or endogenous long chain n-3 PUFAs. Exogenous 
and endogenous introduction of long chain n-3 PUFAs increased n-3 PUFA levels in 
mast cells and inhibited degranulation, lipid-derived mediator release and 
F\WRNLQHFKHPRNLQHSURGXFWLRQIURPPDVWFHOOVDFWLYDWHGWKURXJK)Fİ5,  
In response to IgE/antigen, mast cells release preformed mediators in seconds, 
lipid-derived mediators in minutes, and cytokines/chemokines within hours. Many of the 
mediators play important roles in the process of inflammation. The degranulation 
process results in a very quick (within seconds) release of preformed mediators to the 
extracellular environment. These mediators include histamine, heparin, tryptase, 
chymase, major basic protein and more (Galli et al., 2005). Among them, histamine is 
one of the best-studied mediators from mast cells that contribute to allergic 
inflammation both directly and indirectly (MacGlashan, 2003). Mast cells are one of the 
four well-recognized histamine-producing cells, along with basophils, gastric 
enterochromaffin-like cells, and histaminergic nerves in the brain (Parsons and Ganellin, 
2006). Directly, histamine can increase vascular permeability, cause vasodilation, and 
induce constriction of smooth muscle cells expressing H1 receptors. Indirectly, 
histamine triggers the release of pro-inflammatory cytokines and enhances adhesion 
molecule expression on T cell, and also triggers pain (Thurmond et al, 2008).  
The second group of mast cell mediators, lipid-derived mediators, can be produced 
from n-3 (EPA) and n-6 PUFAs (AA and dihomo-Ȗ-linolenic acid (DGLA)) (Khanapure 
et al., 2007). EPA is the precursor of 3-series PGs and 5-series LTs. Whereas AA is the 
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precursor of 2-series PGs and 4-series LTs (including cys-LTs). DGLA is the precursor 
of 1-series prostaglandins. However, prostaglandins and leukotrienes derived from EPA 
have lower pro-inflammatory potential than those from AA. Cys-LTs have a strong 
effect on smooth muscle contraction, and increased vascular permeability compared to 
5-series LTs. Cys-LTs can induce eosinophil migration (Fregonese et al., 2002), and 
activate eosinophils and mast cells to secret cytokines (Hallstrand and Henderson, 
2010). One-series PGs are anti-inflammatory, but the level of DGLA in body is very low 
(Wang et al., 2012). In HepG2 human hepatic cells, the level of AA is 7-fold higher than 
the combination of EPA and DHA, and DGLA is not detectable (Yousefi et al., 2012). In 
mouse liver tissue, the percentage of AA is comparable to the combination of EPA and 
DHA and 10-fold higher than DGLA (Kelley et al., 2006). New non-classical 
eicosanoids, protectins and resolvins, were reported to be generated from EPA and 
DHA, which are all anti-inflammatory (Kohli and Levy, 2009). Furthermore, EPA and 
AA are using the same enzymes for eicosanoid production, which means competitive 
inhibition on pro-inflammation eicosanoid production from n-6 PUFAs. So in general, 
n-3 PUFAs would be considered to be protective against inflammation compared to n-6 
PUFAs.  
The massive production of cytokines/chemokines requires gene transcription and 
translation, so are the last mediators to be synthesized and released. TNF and CCL2 are 
well-documented pro-inflammatory cytokine and chemokine. Some of the key actions 
of TNF are to trigger the release of pro-inflammatory cytokines/chemokines from 
macrophages, modulating T cell activation, inducing adhesion molecule expression on 
endothelial cells, and promoting endothelial cell apoptosis (Zelova and Hosek, 2013). 
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CCL2 recruits macrophages, T cells and dendritic cells to sites of inflammation, and 
also activates endothelial cells to produce cytokines such as IL-6, and enhance adhesion 
molecule expression in endothelial cells, such as intercellular adhesion molecule-1 
(ICAM-1) (Conti and DiGioacchino, 2001).  
Our data supports earlier observations that long chain n-3 PUFAs have direct 
effects on mast cell function. In calves, diets enriched in long chain n-3 PUFAs were 
found to reduce mast cell infiltration in gastrointestinal tract induced by helminthes 
infection (Muturi et al., 2005). DHA and ALA treatment was reported to decrease 
tryptase activity, reduce PGE2 production and histamine release in canine mastocytoma 
cells activated by the wasp venom peptide, mastoparan (Gueck et al., 2004a; Gueck et 
al., 2003). ALA decreases histamine release in RBL-2H3 rat basophilic leukemia cells 
activated by antigen and calcium ionophore A23187 (Kawasaki et al., 1994). In MC/9 
mouse mast cells, 6,9,12,15,18,21-tetracosahexaenoic acid (24:6 n-3), EPA and DHA 
not only decreased the level of LTB4, LTC4, 5-hydroxyeicosatetraenoic acid and 
histamine in resting cells, but also suppressed histamine release from antigen-activated 
cells (Ishihara et al., 1998). In mouse BMMC, long chain n-3 PUFAs suppressed 
expression of IL-4, IL-5 and IL-13 at both the gene and protein levels and decreased 
nuclear expression of GATA-1, 2 (Park et al., 2013). In rat peritoneal mast cells 
activated with calcium ionophore A23187, and mast cells isolated from tunica mucosa 
bronchiorum of guinea pig challenged with ovalbumin, long chain n-3 PUFAs are 
associated with decreased synthesis of PGD2 and 4-series LTs (Kuwamori et al., 1997; 
van Haaster et al., 1993). In human mast cell line HMC-1 stimulated with 
ionomycin/PMA, EPA and DHA incubation decreases production of reactive oxygen 
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species (ROS) and Th2 cytokines, such as IL-4, IL-13, by suppressing MAPK activation 
(van den Elsen et al., 2013). In a study using mast cells derived from human umbilical 
cord mononuclear cells, EPA supplementation showed inhibitory effect on PGD2 
production after challenging cells with IgE/anti-IgE (Obata et al., 1999).   
However, these previous studies provided little evidence on the effects of long 
chain n-38)$VRQ)Fİ5,-mediated activation of mast cells and did not address the 
mechanisms by which long chain n- 38)$V PRGXODWHG PDVW FHOO IXQFWLRQV )Fİ5,
mediate the principle signaling pathway through which mast cells are activated during an 
atopic allergen-driven inflammatory response (Gilfillan and Tkaczyk, 2006). 
Furthermore, some studies have suggested that long chain n-3 PUFAs may potentiate 
mast cell mediator synthesis and release. For example, EPA dissolved in ethanol was 
reported to increase degranulation, TNF release, ROS production, and enhance Syk 
phosphorylation in RBL-2H3 cells upon anti-TNP IgE/TNP stimulation (Nakano et al., 
2005). In C2 canine mastocytoma cells, EPA was reported to increase production of 
PGE2 and histamine release after stimulating cells with mastoparan (Gueck et al., 
2004b). 
In the present study, primary bone marrow-derived mast cells and human LAD2 
mast cells were supplemented with long chain n-3 PUFAsfollowed with activation  
WKURXJK )Fİ5, EPA supplementation reduced degranulation in LAD2 cells and 
BMMC, inhibited lipid-derived mediator release, and cytokine/chemokine production 
from BMMC with increased EPA level in the cells. DHA-Na treatment had no effect on 
degranulation of LAD2 cells and there was no difference between 24 hr and 48 hr 
treatment of DHA-Na on LAD2 degranulation, which raise the possibility that DHA 
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may require longer time to have effect on degranulation of LAD2 cells. Incorporation of 
DHA inhibited degranulation and suppressed cytokine/chemokine production from 
BMMC, but not cys-LT release, while EPA inhibited cys-LT release from BMMC. The 
reason is that EPA, instead of DHA, is the precursor for LTs (Calder, 2013). 
Furthermore, in addition to exogenous supplementation model, a fat-1 transgenic model 
was used to confirm the results of exogenous model. Fat-1 mouse is a model with unique 
merits for studies with n-3 PUFAs because the fat-1 mice have a modified n-3/n-6 PUFA 
profile and the confounding factor of diet which exists in diet intervention studies is 
diminished. The mice are genetically modified with fat-1 gene from a non-parasitic 
nematode C. elegans, which encodes an n-3 fatty acid desaturase and enables the animal 
to endogenously produce n-3 from n-6 PUFAs endogenously (Kang et al., 2004). 
BMMC generated from fat-1 transgenic mice displayed the expected modified fatty acid 
profile without any effect on the mast cell phenotype. As expected, fat-1 transgenic 
BMMC had higher EPA (20:5 n-3), DPA (22:5 n-3), DHA (22:6 n-3, close to be 
significant) levels and lower AA (20:4 n-6) level, compared to BMMC generated from 
WT mice. The results showed that fat-1 BMMC had reduced levels of degranulation, 
lipid-derived mediator synthesis and release, as well as cytokine and chemokine 
production compared to WT BMMC after IgE/antigen stimulation. The effects may be 
attributed to higher EPA and DPA levels, and lower AA in fat-1 BMMC. In the present 
study, endogenous model showed reduced degranulation, cys-LT release and 
cytokine/chemokine production in fat-1 BMMC. In exogenous model, however, EPA 
incorporation  did not influence TNF production in BMMC. DHA incorporation did not 
alter cys-LT release in BMMC. The reason might be attributed to the altered n-3 and n-6 
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PUFA profile in fat-1 BMMC (increase in EPA, DPA and DHA levels, and decease in AA 
levels). In contrast, inthe exogenous supplementation model, EPA-Na treatment increased 
EPA and DPA levels, but not DHA and AA levels. DHA-Na treatment only increased DHA 
level, but not any other PUFAs. 
As shown in exogenous model, there is a difference between incorporations of EPA 
and DHA on mediator release from BMMC. It appears that EPA may be more effective 
in inhibiting mediator release that does not require gene expression (i.e. preformed and 
lipid-derived mediators), while DHA is more effective in reducing cytokine/chemokine 
production in BMMC. This may occur because EPA in contrast to DHA is precursor for 
PGs and LTs. In addition, with two more carbons and one more double bond, the 
incorporation of DHA causes an even looser organization of the membrane (higher 
membrane fluidity) than EPA (Hashimoto, 1999). Furthermore, EPA and DHA 
supplementation inhibited degranulation in BMMC, but only EPA supplementation 
decreased degranulation in LAD2 cells, which indicates that different cells have 
different response to long chain n-3 PUFAs.  
The possible mechanisms by which long chain n-3 PUFAs regulate mast cell 
functions are:  1) Long chain n-3 PUFAs, simply by their incorporation into the 
membrane, may influence membrane structure and function (Jump, 2002). 2) EPA and 
DHA are precursors for eicosanoids (PGs, LTs, resolvins) and competitive substrates 
with AA, and may change the profile of eicosanoid production in body (Tapiero et al., 
2002). 3) They may function through the free fatty acid receptors, G-protein coupled 
receptor (GPR)40 and GPR120 ( Briscoe et al, 2003; Oh and Olefsky, 2012). 4) Long 
chain n-3 PUFAs can regulate gene transcription directly through peroxisome 
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proliferator-activated receptors (PPARs) (Zuniga et al., 2011). An interesting 
phenomenon shown in the present study was that AA-Na supplementation also showed 
inhibitory effects on degranulation (LAD2 cells and BMMC) and CCL2 production 
(BMMC). Some studies showed that AA can modulate membrane/lipid raft structure and 
function. Increase membrane fluidity caused by AA supplementation was reported on a 
broad range of cell types such as macrophages, endothelial cells and neurons (Rietjens et 
al., 1987; Villacara et al., 1989; Yang et al., 2011). AA supplementation was shown to 
increase the AA content of both rafts and non-raft regions in C2 mast cells (Basiouni et 
al., 2012). 
In summary, the current study provided evidence for inhibitory effects of long 
chain n-3 PUFAs on mediator release from mast cells activated through WKH )Fİ5,
signaling pathway. Exogenous supplementation and endogenous production of n-3 
PUFAs have similar effects on mast cell activation ± even though endogenous 
production of n-3 PUFAs results in a greater alteration on fatty acid profile. EPA may be 
more potent on inhibiting mediator release that do not require gene expression 
(preformed and lipid-derived mediators), while DHA is more affective on suppressing 
cytokine/chemokine production. 
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CHAPTER 3  
LONG CHAIN N-3 POLYUNSATURATED FATTY ACIDS 
INHIBIT )Fİ5,-MEDIATED SIGNAL TRANSDUCTION 
BY ALTERING EXPRESSION OF SIGNALING 
MOLECULES AND DISRUPTING )Fİ5,ASSOCIATION 
WITH LIPID RAFTS 
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3.1 Abstract 
Aim of the study: n-3 polyunsaturated fatty acids (PUFAs) were shown to inhibit 
mediator release from mast cells activated through Fc İ receptor I ()Fİ5,). This study is 
to evaluate how long chain n-3 PUFAs alter )Fİ5,-mediated signal transduction. 
Methodology: The total expression and phosphorylation of Lyn, spleen tyrosine kinase 
(Syk) and linker of activated T cells (LAT) in wild type (WT) and fat-1 bone 
marrow-derived mast cells (BMMC) before and after activation was measured by 
western blot analysis)Fİ5,FHOOVXUIDFHH[SUHVVLRQLQ%00&DQGODERUDWRU\RIDOOHUJLF
diseases 2 (LAD2) cells were evaluated by flow cytometry. Lipid rafts were isolated by 
sucrose gradient centrifugation. Fatty acid profile in lipid rafts was measured by 
GC-MS. )Fİ5,H[SUHVsion in whole cell and lipid raft were determined by western blot 
analysis.  
Results: The phosphorylation of Lyn, Syk and LAT, and total expression of Lyn and 
LAT were decreased in fat-1 BMMC. The cell surface and whole cell expression of 
)Fİ5,Zere not changed in fat-1 BMMC and long chain n-3 PUFA-treated BMMC and 
LAD2 cells+RZHYHU)Fİ5,H[SUHVVLRQLQOLSLGUDIWVZDVGHFUHDVHGLQfat-1 BMMC and 
mast cells supplemented with long chain n-3 PUFAs. After eicosapentaenoic acid (EPA) 
VXSSOHPHQWDWLRQ WKH H[SUHVVLRQ RI )Fİ5, LQ OLSLG UDIWV RI ERWK UHVWLQJ DQG DFWLYDWHG
BMMC was reduced compared to control. long chain n-3 PUFA levels were increased in 
lipid rafts of fat-1 BMMC compared to WT.  
Conclusion: Long chain n-3 PUFAs inhibit Fcİ5,-mediated signal transduction in mast 
cells, by reducing the expression of Lyn and LAT and GLVUXSWLQJ)Fİ5,association 
with lipid rafts through altering lipid raftfatty acid profile.  
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3.2 Introduction 
In chapter 2, n-3 polyunsaturated fatty acids (PUFAs) were shown to inhibit Fc İ 
receptor I ()Fİ5,)-mediated mast cell degranulation and lipid-derived mediator and 
cytokine/chemokine production and release, both exogenously and endogenously, which 
VXJJHVWV)Fİ5,-mediated signal transduction was inhibited by long chain n-3 PUFAs.  
)Fİ5, LV H[SUHVVHG RQ PDVW FHOOs DV D WHWUDPHU ZKLFK FRQWDLQV RQH Į FKDLQ IRU
immunoglobulin E (IgE) ELQGLQJRQHȕDQGWZRȖFKDLQVIRUVLJQDOWUDQVGXFWLRQXVLQJ
the immunoreceptor tyrosine-based activation motifs (ITAMs) (Fig. 1.1). The 
cross-linking of IgE-ERXQG )Fİ5, ZLWK PXOWLYDOHQW DQWLJHQ UHVXOWV LQ WKH
phosphorylation of ITAMs by Lyn kinase. Phosphorylated ITAMs recruit and activate 
spleen tyrosine kinase (Syk) (Johnson et al., 1995), which activates protein kinase C 
(PKC). PKC mediates degranulation and the activation of transcription factor, nuclear 
factor ʃ-light-chain-enhancer of activated B cells (NF-ț%6\NDOVRSKRVSKRrylates the 
linker of activated T cells (LAT), which is an adaptor protein mediating the activation of 
phospholipase C-Ȗ (PLC-Ȗ) (Siraganian et al., 2010). PLC-ȖJHQHUDWHVGLDF\OJO\FHURO
(DAG) and inositol 1,4,5 trisphosphate (IP3) from phosphatidylinositol 
4,5-bisphosphate (PIP2), which activates PKC (Teixeira et al., 2003) and releases 
calcium from the endoplasmic reticulum (ER) (Taylor and Thorn, 2001). Another 
adaptor protein, growth factor receptor-bound protein 2 (Grb2), is also activated by 
phosphorylated LAT, which mediates the activation of mitogen-activated protein kinase 
(MAPK) pathways and activator protein 1 (AP-1) transcription factor activation (Fig. 
1.3). Cytosolic phospholipases A2 (cPLA2) can be activated by ERK, which causes the 
release of eicosapentaenoic acid (EPA, n-3) and arachidonic acid (AA, n-6) from 
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membranes (Fujishima et al., 1999). Cyclooxygenases (COX) and lipoxygenases (LOX) 
act on EPA and AA to produce eicosanoids (Vane, 1971).  
7KXV )Fİ5,-mediated signal transduction requires precise interactions with 
membrane-proximal second messengers, thought to occur on discrete cholesterol-rich 
microdomains termed as lipid rafts (Simons and Toomre, 2000; Siraganian et al., 2010). 
Lipid rafts function as platforms for receptor-ligand binding and cross-linking and are 
distinct from non-raft membrane regions because they contain high levels of cholesterol, 
sphingolipids, transmembrane proteins, acylated proteins, and 
glycophosphatidylinositol (GPI)-anchored proteins. The content of saturated fatty acids 
is thought to be higher in lipid rafts compared to other regions (Lingwood and Simons, 
2010). The special composition of lipid rafts causes the rafts to be more tightly packed, 
and results in a liquid-ordered state, allowing them to facilitate incredibly rapid signaling 
events. Lipid rafts are thought to have concentrated molecules required for signaling and 
a more stable membrane local environment, thus making them an ideal platform for 
)Fİ5,-mediated signal transduction (Barua and Goldstein, 2012; Lingwood and Simons, 
2010), because the signal transduction PHGLDWHG E\ )Fİ5, LV LQFUHGLEO\ TXLFN 7KH
preformed mediators can be released within seconds.  
n-3 PUFAs are components of phospholipids and sphingolipids, the two main 
forms of membrane lipids. Since unsaturated fatty acyl chains have a less tendency to 
pack together, n-3 PUFAs may alter raft property and IXQFWLRQWKXVPRGLI\LQJWKHFHOO¶V
response to receptor-mediated stimuli. Recently, it has been suggested that changes in 
the lipid component of lipid rafts can disrupt the signal transduction mediated by some 
receptors. In human T cells, docosapentaenoic acid (DHA) was shown to inhibit IL-2 
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receptor signal transduction by increasing n-3 PUFA levels and decreasing n-6/n-3 ratio 
in lipid rafts. Signal transducer and activator of transcription (STAT)5a and STAT5b 
recruitment to lipid rafts were inhibited as a result of reduced IL-2 receptor expression in 
lipid rafts (Li et al., 2005). In human breast cancer cells, eicosapentaenoic acid (EPA) 
and DHA treatments inhibit epidermal growth factor receptor (EGFR) expression in 
lipid rafts and EGFR signal transduction by decreasing levels of sphingomyelin, 
cholesterol, and DAG in lipid rafts (Schley et al., 2007).  
Long chain n-3 PUFA supplementation increases n-3 PUFA levels in both raft and 
non-raft regions of membranes from canine mastocytoma cells (Basiouni et al., 2012). 
Thus, we hypothesized that long chain n-3 PUFAs alter lipid raft propertyin mast cells 
DQG PRGLI\ WKH G\QDPLF SDUWLWLRQLQJ RI )Fİ5, WKHUHE\ LQKLELW WKH VLJQDOLQJ HYHQWV
LQLWLDWHGE\)Fİ5,FURVV-linking. The expression of some signaling proteins may also be 
influenced by long chain n-3 PUFAs, because long chain n-3 PUFAs may bind to free 
fatty acid receptors and  peroxisome proliferator-activated receptors (PPARs) to 
modulate gene transcription (Calder, 2012). To test this hypothesis, we used two models 
of long chain n-3 PUFA incorporation: 1) Long chain n-3 PUFAs were exogenously 
supplemented to laboratory of allergic diseases 2 (LAD2) cells and wild type (WT) bone 
marrow-derived mast cell (BMMC) in culture; 2) BMMC were cultivated from bone 
marrows of fat-1 transgenic mice, which have enhanced long chain n-3 PUFA levels and 
decreased n-6 PUFA levels endogenously. The effect of long chain n-3 PUFAs on 
)Fİ5,-mediated signal transduction in mast cells ZDVH[DPLQHGLQWKHFRQWH[WRI)Fİ5,
distribution and mobilization in lipid rafts and early phosphorylation events.   
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3.3 Materials and Methods 
3.3.1 Growth of mouse BMMC and human LAD2 cells  
The method is the same as described in chapter 2, section 2.3.2.  
3.3.2 Fatty acid supplementation to BMMC and LAD2 cells 
The method is the same as described in chapter 2, section 2.3.5. 
3.3.3 Flow cytometry  
The method is the same as described in chapter 2, section 2.3.4. Mean 
fluorescence intensity (MFI), which represents the shift of fluorescence intensity in the 
cell population measured, was generated using WinMDI 2.9 software.  
3.3.4 Lipid raft isolation  
Lipid rafts were isolated by sucrose gradient centrifugation modified from Brown 
(Brown, 2002). Two hundred million cells were collected and washed with ice-cold 
Tris/NaCl/EDTA (TNE) buffer. Cells were then lysed on ice with 1% Triton X-100 
dissolved in TNE/P buffer (TNE supplemented with 0.2 mM phenylmethylsulfonyl 
fluoride (Sigma-Aldrich, Oakville, ONȝJPO leupeptin (Sigma-$OGULFKDQGȝJPO
pepstatin (Sigma-Aldrich)). Cell lysate was mixed with ice-cold TNE/P buffer 
containing 80% (w/v) sucrose before transferring to a 14 × 89 mm ultracentrifuge tube 
(Beckman Coulter, Mississauga, ON). Cell lysate/80% sucrose mixture was then 
overlaid by ice-cold TNE/P buffer containing 35% (w/v) sucrose which was covered to 
the top by ice-cold 5% (w/v) sucrose in TNE/P buffer (Fig. 3.1A). After centrifugation 
with a SW-41 rotor (Beckman Coulter) for 3 hours (hr) at 100, 000× g at 4°C, a visible 
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band of lipid raft fraction was harvested at the 5%/35% sucrose interface (Fig. 3.1B). 
The lipid raft fraction was then transferred to a new ultracentrifuge tube, diluted with 
ice-cold TNE/P buffer, and centrifuged for 1 hr at 100, 000× g at 4°C. After removing 
the supernatant, the pellet was re-VXVSHQGHG LQ  WR  ȝO 71(3 EXIIHU DQG
centrifuged for 10 minutes (min) at 14, 000 rpm at 4°C. The supernatant was discarded 
and the pellet dissolved directly in 2× SDS sample buffer (Life Technologies, 
Burlington, ON), prior to boiling for 5 min. 
 
 
 
 
 
 
 
 
 
 
 
 
 

132 
 
3.3.5 Gas chromatography-mass spectrometry (GC-MS) of lipid rafts  
The fatty acid profile of lipid rafts was measured by GC-MS using method 
described in chapter 2, section 2.3.8.  
3.3.6 /LSLGUDIWLGHQWLILFDWLRQDQG)Fİ5,GLVWULEXWLRQ 
For lipid raft identification, thirteen fractions were collected from the top of the 
gradient tube with 1 ml from each lysate fractionation (Fig. 3.1) by sucrose gradient 
centrifugation as mentioned above. After boiling in 2× SDS sample buffer (Life 
Technologies) for 5 min, lipid raft marker Lyn expression in each fraction was 
evaluated by western blot analysis.   
)RU )Fİ5, GLVWULEXWLRQ PHDVXUHPHQW (3$-Na-treated cells were sensitized with 
500 ng/mL anti-2,4-dinitrophenyl (DNP) IgE (Sigma-Aldrich) for 24 hr, then activated 
with 10 ng/mL DNP-human serum albumin (HSA) (Sigma-Aldrich) for 5 min. After 
cell lysate fractionation by sucrose gradient centrifugation, )Fİ5, H[SUHVVLRQ LQ 13 
fractions was evaluated by western blot analysis.  
3.3.7 Protein isolation from BMMC and LAD2 cells 
Protein was extracted from cells by lysing the cells with lysis buffer containing 
1% Triton X-100, 1× complete protease inhibitor cocktail (Roche Molecular 
Biochemicals, Indianapolis, IN), 1× protease inhibitor cocktail (Sigma-Aldrich), 50 
ȝJPOGLFKORURLVRFRXPDULQ 5RFKH0ROHFXODU%LRFKHPLFDOVP0Eenzamidine 
(Sigma-Aldrich), 1 mM sodium orthovanadate (Sigma-Aldrich), 5.4 mM sodium 
pyrophosphate (Sigma-Aldrich), and 50 mM sodium fluoride (Sigma-Aldrich) in 
tris-buffered saline (TBS). After measuring the protein concentration using the 
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Bradford protein assay (Sigma-Aldrich) (Bradford, 1976), the protein concentration for 
each sample was adjusted to the same level with lysis buffer. Finally, samples were 
boiled for 5 min in 4× NuPage sample buffer (Life Technologies).  
3.3.8 Western blot analysis 
Whole cell protein, lipid raft, and gradient fraction samples were electrophoresed 
on a NuPage Novex 4-12% Bis-Tris Gel (Life Technologies) at 200 V for 30 min. 
Then, the separated proteins were transferred to a nitrocellulose membrane (Life 
Technologies) at 30V for 1 hr. Membranes were then removed and washed with TBST 
(TBS containing 0.05% tween-20). After blocking with 5% nonfat milk in TBST at 4°C 
overnight, membrane was probed with rabbit polyclonal anti-mouse Lyn, pho-Lyn, Syk, 
pho-Syk, LAT and Pho-LAT antibodies (Cell Signaling Technology, Danvers, 
Massachusetts), rabbit polyclonal anti-mouse and anti-human )Fİ5,Į antibodies (Santa 
Cruz Biotechnology, Santa Cruz, California) and mouse monoclonal anti-actin antibody 
(Sigma-Aldrich) diluted with 5% nonfat milk in TBST at room temperature for 3 h. 
Membranes were then washed with TBST three times for 15 min each and incubated 
with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Santa Cruz 
Biotechnology)  and HRP-conjugated goat anti-mouse IgG (Santa Cruz 
Biotechnology) diluted with 5% nonfat milk in TBST at room temperature for 1 hr. 
After washing with TBST three times for 15 min each, the blot was developed in 
chemiluminescent peroxidase substrate (Sigma-Aldrich) for 1 min and exposed to 
ultraviolet (UV) light in a ChemiDoc XRS system (BD Biosciences, Mississauga, ON) 
for image acquisition.  
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3.3.9 Statistical analysis 
The differences in protein expression and fatty acid profile between WT and fat-1 
BMMC were determined using Student's t-test. The differences between the 
PUFA-treated cells were evaluated by one-way analysis of variance (ANOVA) followed 
by the post-hoc Bonferroni test. Two-way ANOVA followed by the post-hoc Bonferroni 
test was used to determine the difference of expression and phosphorylation of signaling 
molecules at different time points between WT and fat-1 BMMCs, and of the 
GLVWULEXWLRQRI)Fİ5, LQGLIIHUHQW IUDFWLRQV6WDWLVWLFDO VLJQLILFDQFHZDVVHW DW p<0.05. 
Statistical analysis was performed using SPSS 11.5 statistical software package (IBM 
Corporation, Armonk, NY).   
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3.4 Results 
3.4.1 The effects of long chain n-38)$VRQ)Fİ5,-mediated signal transduction 
in BMMC 
IgE/antigen induced a significant increase in phosphorylation of Lyn, Syk, and LAT after 5 
min which reached a maximum at 10-25 min. Fat-1 BMMC had lower phosphorylation of 
Lyn, Syk, LAT compared to WT BMMC after DNP-HSA stimulation. For example, 
after 10 min DNP-HSA activation, the phosphorylation of Lyn, Syk and LAT in fat-1 
BMMC were 28% (p=0.044), 30.1% (p=0.035) and 33% (p=0.011), respectively, lower 
than in WT BMMC (Fig. 3.2). Fat-1 BMMC expressed lower amounts of Lyn and LAT. 
In unstimulated cells, the expression of total Lyn and LAT in fat-1 BMMC were 29.8% 
(p=0.006) and 33.9% (p=0.031), respectively, lower than in WT BMMC (Fig. 3.2).  
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3.4.2 The effects of long chain n-38)$VRQ)Fİ5,H[SUHVVLRQRQWKHFHOOVXUIDFHRI
mast cells 
WT BMMC and fat-1 BMMC expressed FRPSDUDEOHOHYHOVRI)Fİ5,RQWKHFHOO
surface (Fig. 3.3). In addition, EPA-Na, DHA-Na, AA-Na supplementation did not alter 
)Fİ5,FHOOVXUIDFHH[SUHVVLRQLQ%00&DQG/$'FHOOV)LJ and 3.5).  
 
 
 
 
 
 
 

139 
 
 
 
)LJXUH)Fİ5,H[SUHVVLRQVRQWKHFHOOVXUIDFHRIlong chain PUFA-supplemented 
WT BMMC. WT BMMC were first treated with 100 µM EPA-Na, DHA-Na, and 
AA-1DIRUKU7KH0),RIFHOOVXUIDFH)Fİ5,ZDVWKHQPHDVXUHGE\IORZF\WRPHWU\ 
and is compared to untreated control. Error bars represent SEM (n=3). MFI: Mean 
fluorescence intensity. 
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)LJXUH)Fİ5, expressions on the cell surface of long chain PUFA-supplemented 
LAD2 cells. LAD2 cells were first treated with 100 µM EPA-Na, DHA-Na, and AA-Na 
IRUKU7KH0),RIFHOOVXUIDFH)Fİ5,ZDVWKHQPHDVXUHGE\IORZF\WRPHWU\ and is 
compared to untreated control. Error bars represent SEM (n=3). MFI: Mean 
fluorescence intensity. 
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3.4.3 The effects of long chain n-38)$VRQ)Fİ5,H[SUHVVLRQLQZKROHPDVWFHOOV 
There was no GLIIHUHQFH LQ ZKROH FHOO )Fİ5, H[SUHVVLRQ EHWZHHQ :7 DQG fat-1 
BMMC (Fig. 3.6). In addition, EPA and DHA supplementation did not change whole 
FHOO)Fİ5,H[SUHVVLRQLQ%00&+RZHYHU$$VXSSOHPHQWDWLRQLQFUHDVHGZKROHFHOO
)Fİ5,H[SUHVVLRQp=0.002, Fig. 3.7). In human mast cells LAD2 cells, EPA, 
DHA, and AA supSOHPHQWDWLRQDOOKDGQRHIIHFWRQ)Fİ5,H[SUHVVLRQ LQZKROHFHOOV
(Fig. 3.8).  
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3.4.4 Lipid raft isolation, identification and fatty acid composition determination 
The raft fraction (fraction 2) expressed high level of Lyn and almost no actin (Fig. 
3.9), which supports the success of lipid raft isolation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
 
Figure 3.9 Lipid raft identification with raft marker Lyn. Lyn and actin 
(microfilament protein) expression in 13 fractions of sucrose gradient after 
centrifugation were measured by western blot analysis. Data is the representative of 
three independent experiments with similar results.  
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Eight fatty acids were identified (palmitic acid (16:0), stearic acid (18:0), oleic acid 
(18:1 n-9), linoleic acid (18:2 n-6), AA (20:4 n-6), EPA (20:5 n-3), docosapentaenoic 
acid (DPA, 22:5 n-3), and docosahexaenoic acid (DHA, 22:6 n-3)) in lipid rafts of WT 
and fat-1 BMMC. The GC-MS results showed that lipid rafts of fat-1 BMMC contain 
significantly higher levels of EPA and DPA (p=0.020 and p=0.030), as shown in Fig. 
3.10 and Table 3.1. The ratio of n-6/n-3 was significantly reduced in lipid rafts of fat-1 
BMMC (p=0.048) compared to WT BMMC. The level of palmitic acid in lipid rafts of 
fat-1 BMMC was significantly deceased compared to WT BMMC (p=0.035).   
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Table 3.1 Fatty acid composition of lipid rafts of WT and fat-1 BMMC  
Fatty acids Percentage of total fatty acids (%) WT BMMC fat-1 BMMC 
16:0 23.85 ± 1.72 7.12 ± 0.99* 
18:0 24.17 ± 3.15 25.74 ± 7.63 
18:1 n-9 15.31 ± 2.79 16.45 ± 0.77 
18:2 n-6 9.92 ± 2.84 7.12 ± 2.25 
20:4 n-6 (AA) 7.23 ± 2.45 4.53 ± 1.09 
20:5 n-3 (EPA) 2.12 ± 0.04 7.79 ± 0.49* 
22:5 n-3 (DPA) 5.13 ± 1.76 21.01 ± 6.40* 
22:6 n-3 (DHA) 12.27 ± 1.72 10.24 ± 3.81 
n-6/n-3 ratio 0.87 ± 0.12 0.30 ± 0.07* 
Values are mean ± SEM, n=3.  
*: p<0.05, compared with WT BMMC, Student's t-test. 
AA: Arachidonic acid; DHA: Docosahexaenoic acid; DPA: Docosapentaenoic acid; EPA: 
Eicosapentaenoic acid; WT: Wild type. 
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3.4.5 The effects of long chain n-38)$VRQH[SUHVVLRQRI)Fİ5,LQOLSLGUDIWVRI
mast cells 
The H[SUHVVLRQRI)Fİ5,LQOLSLGUDIWVLVRODWHGIURP:7%00&ZHUHKLJKHU
%, p=0.003) than in lipid rafts from fat-1 BMMC (Fig. 3.11). In WT BMMC, EPA and 
'+$ VXSSOHPHQWDWLRQ GHFUHDVHG )Fİ5, H[SUHVVLRQ LQ OLSLG UDIWV  p=0.014; 
49.1%, p=0.030, respectively; Fig. 3.12). EPA, DHA and AA supplementation also 
VLJQLILFDQWO\UHGXFHG)Fİ5,H[SUHVVLRQ LQ OLSLG UDIWVRI/$'FHOOV p=0.001; 
51.7%, p<0.001; 50.2%, p<0.001; Fig. 3.13). 
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3.4.6 The effects of long chain n-38)$VRQ)Fİ5,GLVWULEXWLRQLQ%00&ZLWK
and without activation 
,QWKHDEVHQFHRI,J(DQWLJHQ)Fİ5,ZDVGHWHFWHGLQrafts of untreated BMMC and 
EPA-Na-treated BMMC. However, EPA-1DWUHDWPHQWGHFUHDVHG)Fİ5,ORFDOL]DWLRQWR
fraction 2 (p  ,Q DGGLWLRQ )Fİ5, ZDV UHORFDOL]HG WR IUDFWLRQ  p=0.026), 5 
(p<0.001) and 13 (p=0.039) in EPA-Na-treated BMMC, compared to untreated control 
(Fig. 3.14A and B). After IgE/antigen stimulation, in both untreated and EPA-Na-treated 
FHOOV)Fİ5,ZDVFRQFHQWUDWHGWRIUDFWLRQ (Fig. 3.14C and D). However, there was less 
)Fİ5, in fraction 2 (p<0.001) in EPA-Na-treated BMMC. In addition, )Fİ5, was 
re-localized to fraction 9 (p=0.035), 10 (p=0.041), and 13 (p=0.044) in EPA-Na-treated 
cells.  
 
 
 
 
 
 
 
 
155 
 
 
)LJXUH  )Fİ5, GLVWULEXWLRQ LQ (3$-supplemented BMMC with and without 
activation. $:HVWHUQEORWDQDO\VLVRI)Fİ5,GLVWULEXWLRQLQraft fractions of WT 
BMMC treated with or without 100 µM EPA-Na for 24 h. The data are the representative 
of three independent experiments with similar results. (B) The density percentage of 
)Fİ5,WRWRWDOLQraft fractions of WT BMMC treated with or without 100 µM 
EPA-1D IRU  K & :HVWHUQ EORW GHWHUPLQDWLRQ RI )Fİ5, GLVWULEXWLRQ LQ  raft 
fractions of WT BMMC treated with or without 100 µM EPA-Na for 24 h, followed with 
500 ng/mL anti-DNP IgE sensitization for 24 h and 10 ng/mL DNP-HSA stimulation for 
5 min. The data are the representative of three independent experiments with similar 
UHVXOWV '7KHGHQVLW\SHUFHQWDJHRI)Fİ5,  WR WRWDO LQ  raft fractions of WT 
BMMC treated with or without 100 µM EPA-Na for 24 h, followed with 500 ng/mL 
anti-DNP IgE sensitization for 24 h and 10 ng/mL DNP-HSA stimulation for 5 min. 
Error bars represent SEM (n=3). *: p<0.05, compared with control group, two-way 
ANOVA followed by the post-hoc Bonferroni test.  
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3.5 Discussion 
In this study, for the first time we showed long chain n-3 PUFAs inhibit mast cell 
)Fİ5,-mediated signal transduction by reducing the expression of Lyn and LAT and 
PRGLI\LQJ )Fİ5, UHFHSWRU SDUWLWLRQLQJ LQ OLSLG UDIWV WKURXJK DOWHUDWLRQ LQ OLSLG UDIW
property rather than E\FKDQJLQJ)Fİ5,Hxpression on the cell surface and in the whole 
cell. This study proves that the long chain n-3 PUFA suppression of mast cell mediator 
release shown in chapter 2 is because of the inhibited )Fİ5,-mediated signal 
transduction.  
The phosphorylation of ITAMs LQȕDQGȖFKDLQVRI)Fİ5,E\/\QLVUHVSRQVLEOHIRU
WKHLQLWLDWLRQRI)Fİ5,-mediated signaling pathway. Lyn is thought to be phosphorylated 
by autophosphorylation. There are three action models for the phosphorylation of 
ITAMs by Lyn (Bugajev et al., 2010): 1) Receptor cross-linkLQJ DOORZV ȕ
chain-associated Lyn to phosphorylate ITAMs of neighboring UHFHSWRUV)Fİ5,LVQRW
located close enough to Lyn to be activated in the plasma membrane. However, after 
receptor cross-OLQNLQJ)Fİ5,LVFRQFHQWUDWHGLQUDIWVDQGEHFRPHVFORVHHnough to be 
phosphorylated by Lyn localized in rafts. )Fİ5,FURVV-linking causes the suppression 
of protein tyrosine phosphatase, the negative regulator of phosphorylation.The results of 
this study FOHDUO\VXSSRUWWKHVHFRQGPRGHOZKHUHDIWHU,J(DQWLJHQVWLPXODWLRQ)Fİ5,
moves to the raft regions.  
Phosphorylated ITAMs recruit and activate Syk, which activate some important 
signaling molecules, including phosphoinositide 3-kinase (PI3K), PLC-Ȗ 6+2 
domain-containing leukocyte protein 76 (SLP76), LAT, and VAV family of guanine 
nucleotide exchange factors (Mocsai et al., 2010). LAT also mediates the activation of 
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PLC-ȖDQGDQRWKHUDGDSWHUSURWHLQ*UEZKLFK LQGXFHDFWLYDWLRQRI0$3.SDWKZD\
(Sommers et al., 2004). The phosphorylation of Lyn, Syk and LAT were shown to be 
reduced in fat-1 BMMC, which is consistent with the inhibited mediator release in fat-1 
BMMC (chapter 2). In the current study, fat-1 BMMC had lower Lyn and LAT whole 
cell expression than WT BMMC, but not Syk, which suggest that long chain n-3 
38)$V PD\ LQIOXHQFH )FİRI signaling in both posttranslational and transcriptional 
levels. Long chain n-3 PUFAs may regulate gene transcription by binding to free fatty 
acid receptors, GPR40 and GPR120, both are G-protein-coupled receptors (Hirasawa et 
al, 2008). Another way that long chain n-3 PUFAs may alter gene expression is through 
33$5ȖZKLFKKDVEHHQFRQILUPHGWREHH[SUHVVHGLQKXPDQDQGPXULQHPDVWFHOOVDQG
suggested to be involved in suppression of mast cell maturation and IgE/antigen-induced 
mast cell activation (Tachibana et al, 2008; Sugiyama et al, 2000). 
In this study, fat-1 BMMC were shown to have an altered fatty acid profile in rafts 
and therefore )Fİ5,association with lipid rafts was disrupted. We measured the fatty 
acid profile in lipid rafts and showed that lipid rafts of fat-1 BMMC have a long chain 
n-3 PUFA-enriched fatty acid composition (i.e. increased EPA and DPA levels) 
FRPSDUHG WR OLSLG UDIWV RI :7 %00& :H H[DPLQHG )Fİ5, H[SUHVVLRQ RQ WKH FHOO
surface, in cell lysates, and in lipid rafts to determine the effects of long chain n-3 
PUFAs RQ)Fİ5,expression. We showed that long chain n-3 PUFAs GHFUHDVH)Fİ5,
expression primarily in lipid rafts, but not on the cell surface or in whole cells in both 
exogenous and endogenous models. In addition, EPA-Na treatment suppressed )Fİ5,
localization in rafts of resting cells and )Fİ5,shuttling to lipid rafts of activated cells, 
which may partially explain the reduced phosphorylation of Lyn, Syk and LAT in fat-1 
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BMMC. The present study is the first to show that long chain n-38)$VEORFN)Fİ5,
association with lipid rafts in both resting and activated mast cells.  
Lipid rafts are specific membrane microdomains found in plasma membranes and 
some intracellular membranes, such as Golgi complex, in virtually all cell types 
(Lingwood and Simons, 2010; Silveira et al., 2011). Currently, there are three proposed 
models for the involvement of lipid rafts in )Fİ5,-mediated signaling pathway (Draber 
and Draberova, 2002; Simons and Toomre, 2000). One is that receptors are located in 
lipid rafts or move to the raft regions where the receptor cross-linking initiates the 
signaling pathway (Draber and Draberova, 2002). Another model suggests that rafts 
move close to one another and coalesce, thus aggregating proteins including receptors 
(Simons and Toomre, 2000). Once the rafts are combined into a larger microdomain, 
they form complexes with concentrated receptors, signal adaptors, and kinases. In 
addition, the dephosphorylation of tyrosine kinases was suggested to be inhibited in the 
lipid raft local micro-environment (Barua and Goldstein, 2012). The fusion of lipid rafts 
can be mediated by extracellular ligands, such as antibodies, transmembrane proteins, 
such as LAT, and cytosolic molecules, such as Lyn, and cytoskeletal elements, such as 
actin (Simons and Toomre, 2000). In the first and second models, the aggregation of 
receptors in lipid rafts is vital for signaling initiation, which is subject to change as a 
result of alterations in lipid raft component, such as its fatty acid profile. The third model 
postulates that the initiation of signDOLQJFDQEH WULJJHUHGE\)Fİ5,ȕFKDLQ-associated 
Lyn kinase and occurs outside raft regions (Draber and Draberova, 2002). Although not 
HVVHQWLDO WKLV PRGHO FRQFHGHV WKDW WKH DJJUHJDWLRQ RI )Fİ5, in lipid rafts may be 
important for signal amplification and maintenance under some conditions.The results of 
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this study VKRZHG WKDW )Fİ5, FDQ EH IRXQG LQ UDIW UHJLRQV of BMMC in absence of 
IgE/antigen. However, EPA supplementation FDXVHG)Fİ5,WREHORFDOL]HGLQWRQRQ-raft 
UHJLRQV$IWHU,J(DQWLJHQVWLPXODWLRQ)Fİ5,ZDVFRQFHQWUDWHGWRUDIWVDQGUHJLRQVFORVH
to rafts in both untreated and EPA-supplemented cells. However, EPA-supplemented 
FHOOVKDG OHVV)Fİ5,PRYLQJ WR UDIWVDIWHU ,J(DQWLJHQVWLPXODWLRQThe data from the 
present study clearly supports the first model described above. However, the results of 
present study are not completely consistent with a SUHYLRXVVWXG\VKRZLQJWKDW)Fİ5,
can only be detected in rafts after cross-linking (Field et al., 1997). However, RBL-2H3 
cells, which are not a perfect analogue to mast cells, were used in that study. Different 
FXOWXUH FRQGLWLRQV ZHUH UHSRUWHG WR LQIOXHQFH )Fİ5, H[SUHVVLRQ OHYHOV DQG )Fİ5,
isoforms in RBL-2H3 cells using the same growing protocol (Froese et al., 1982). 
)XUWKHUPRUH'13DQGVWUHSWDYLGLQFDXVHGGLIIHUHQWPRGHVRI)Fİ5,DVVRFLDWLRQZLWK
rafts in Field et al¶s study, which suggest )Fİ5, may shuttle differently to lipid rafts 
under different conditions. 
The dLVUXSWLRQRI)Fİ5,ORFDOL]DWLRQLQUDIWVFDXVHGE\long chain n-3 PUFAs may 
be attributed to altered fatty acid profiles in rafts. EPA and DPA levels in rafts of fat-1 
BMMC were increased and palmitic acid (16:0) level was decreased, suggesting a 
change in lipid raft property. In C2 mast cells, EPA and DHA were shown to increase 
EPA and DHA levels in raft and non-raft regions (Basiouni et al., 2012). However, the 
present study is the first to report that raft properties in fat-1 BMMC are altered.  
In conclusion, this study demonstrates that long chain n-3 PUFAs suppress 
)Fİ5,-mediated signal transduction by inhibiting whole cell expression of Lyn and 
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LAT and GLVUXSWLQJ WKH ORFDOL]DWLRQ DQG VKXWWOLQJ RI )Fİ5, WR OLSLG UDIWV WKURXJK
alteration of lipid raft property.  
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CHAPTER 4  
EFFECT OF LIPID RAFT DESTABILIZATION ON 
ACTIVATION OF BONE-MARROW DERIVED MAST 
CELLS (BMMC) GENERATED FROM WILD TYPE AND 
fat-1 MICE 
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4.1 Abstract 
Aim of the study: n-3 polyunsaturated fatty acids (PUFAs) inhibit mast cell activation 
and Fc İ receptor I ()Fİ5,)-mediated signal transduction E\ GLVUXSWLQJ )Fİ5,
localization and shuttling to lipid rafts. This study is to determine if lipid raft disruption 
influences FcİRI-mediated mediator release in wild type (WT) and long chain n-3 
PUFA-enriched mast cells.  
Methodology: WT and fat-1 bone marrow-derived mast cells (BMMC) were treated with 
methyl-ȕ-F\FORGH[WULQ 0%&' WR GHSOHWH FKROHVWHURO ȕ-KH[RVDPLQLGDVH ȕ-hex) 
release, cysteinyl leukotriene (cys-LT) synthesis, and tumor necrosis factor (TNF) and 
CC chemokine ligand 2 (CCL2) production were measured following activation of  
cells with immunoglobulin E (IgE)/2,4-dinitrophenyl-Human serum albumin 
(DNP-HSA)Fİ5,DQG/\QH[SUHVVLRQLQOLSLGUDIWVfollowing MBCD treatment was 
measured by western blot analysis.  
Results: Following MBCD treatment, both WT and fat-1 BMMC had a YHU\ORZȕ-hex 
release, cys-LT synthesis and TNF and CCL2 production. There was no significant 
difference on release of mediators between WT and fat-1 BMMC, except CCL2. The 
H[SUHVVLRQVRI)Fİ5,DQG/\QLQOLSLGUDIWVZHUHDOVRUHGXFHGE\0%&'WUHDWPHQWLQ
both WT and fat-1 BMMC. 
Conclusion: )Fİ5,-mediated mediator release is inhibited by MBCD treatment in both 
WT and fat-1 BMMC. 
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4.2 Introduction 
In chapters 2 and 3, n-3 polyunsaturated fatty acids (PUFAs) were shown to inhibit 
mast cell degranulation, lipid-derived mediator release, and cytokine/chemokine 
production by suppressing Fc İ receptor I ()Fİ5,)-mediated signal transduction)Fİ5,
localization and shuttling in lipid rafts was disrupted by long chain n-3 PUFAs, but not 
cell surface and whole cell expression. The results suggested that lipid rafts play an 
important role in the inhibitory effect of long chain n-3 PUFAs on mast cell activation.  
Lipid rafts are membrane domains containing high levels of cholesterol, 
spingolipid, glycophosphatidylinositol (GPI)-anchored proteins and acylated proteins, 
which have been suggested to function as platforms for signal transduction of receptors, 
LQFOXGLQJ)Fİ5, (Simons and Toomre, 2000). Lipid rafts have been found in plasma 
membranes and Golgi complexes in almost all cell types (Nichols et al., 2001). Lipid 
rafts are thought to be transient, existing in a sub-second time scale (Nichols et al., 
2001). Because of their special content, lipid rafts are thought to be in a liquid-ordered 
state featured with tightly packed and relatively slow-moving lipid (Heberle and 
Feigenson, 2011). This special organization also gives lipid rafts a high melting 
temperature and insolubility in non-ionic detergents (London and Brown, 2000). 
Lipid rafts are thought to contain concentrated molecules needed for signaling, such 
as receptors, adaptors and kinases, so that receptor cross-linking can occur immediately 
after the introduction of ligands. The receptors could also be recruited to rafts after 
ligand encounters. In addition, the interaction between adaptors, ligands and receptors, 
acylated molecules, or cytoskeleton elements can cause small lipid rafts to fuse and form 
bigger rafts (Simons and Toomre, 2000; Staubach and Hanisch, 2011).  
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/LSLGUDIWVDUHHVSHFLDOO\YLWDOIRU)Fİ5,-mediated signal transduction because it 
requires accurate and extensive protein-protein interaction. Many membrane molecules 
are involved, including adapters (such as Linker for Activation of T cells (LAT)), 
kinases (such as Lyn), phosphatidylinositols (such as phosphatidylinositol 4,5- 
bisphosphate (PIP2)), and fatty acids from membrane lipid (Siraganian, 2003). Some 
lipid raft FRPSRQHQWVKDYHEHHQVKRZQWRIDYRU)Fİ5,-mediated signal transduction. For 
example, lipid rafts have high levels of Lyn expression, and the activity of Lyn in rafts is 
higher than in other membrane regions. The lipid raft micro-environment was suggested 
to inhibit Lyn dephosphorylation by  phosphatase (Young et al., 2003). Another raft 
component, flotillin-1, was reported to colocalize with Lyn in rafts and regulate Lyn 
activity by direct binding to it (Kato et al., 2006).  
Cholesterol is a basic structural molecule for lipid rafts. Cholesterol depletion with 
methyl-ȕ-cyclodextrin (MBCD), which is a specific cholesterol binding agent, has been 
widely used to study lipid raft function (Hinzey et al., 2012). MBCD treatment has been 
shown to inhibit IgE/antigen-induced degranulation of RBL-2H3 cells (Yamashita et al., 
2001). However, there is also study showing that MBCD treatment has no effect on 
IgE/antigen-induced mast cell degranulation, but  LQKLELW )Fİ5, SKRVSKRU\ODWLRQ E\
EORFNLQJWKHLQWHUSOD\EHWZHHQ)Fİ5,DQG/\Q(Sheets et al., 1999).  
My previous study has shown that long chain n-3 PUFAs inhibit mast cell mediator 
release induced by )Fİ5,-activation and suppress )Fİ5,-mediated signal transduction, 
partly E\GLVUXSWLQJ)Fİ5, localization and shuttling to lipid rafts (chapter 2 and 3). 
Thus, we hypothesized that the MBCD pretreatment inhibits )Fİ5,-mediated mediator 
release in both normal mast cells and long chain n-3 PUFA-enriched mast cells. WT 
167 
 
and fat-1 bone marrow-derived mast cells (BMMC) activation was evaluated after 
MBCD treatment.  
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4.3 Materials and Methods 
4.3.1 Growth of WT and fat-1 BMMC  
The method was the same as described in chapter 2, section 2.3.2. 
4.3.2 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT) assay 
XTT assay was performed in BMMC after 10 mM MBCD (Sigma-Aldrich, 
Oakville, ON) treatment for 30 minutes (min) with the method described in chapter 2, 
section 2.3.6. 
4.3.3 Degranulation assay 
BMMC were sensitized with anti-2,4-dinitrophenyl (DNP) immunoglobulin E (IgE)  
(Sigma-Aldrich) for 24 hours (hr), followed by treatment with 10 mM MBCD 
(Sigma-Aldrich) for 30 min. Cells were then activated with 0.001, 0.01, 0.1, 1, 10, 100, 
200 or 500 ng/mL of DNP-human serum albumin (HSA) for 30 min (Sigma-Aldrich). 
Degranulation was determined by measuring ȕ-KH[RVDPLQLGDVHȕ-hex) release with 
the method described in chapter 2, section 2.3.9. 
4.3.4 Enzyme-linked immunosorbent assay (ELISA) for cysteinyl leukotrienes 
(cys-LTs), tumor necrosis factor (TNF) and CC chemokine ligand 2 (CCL2)   
BMMC were sensitized with anti-DNP IgE  (Sigma-Aldrich) for 24 hr, followed 
by treatment with 10 mM MBCD (Sigma-Aldrich) for 30 min. Cells were then activated 
by 1, 10, 100, 200 or 500 ng/mL of DNP-HSA  (Sigma-Aldrich) for 3 hr for LT release 
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and 6 hr for cytokine/chemokine production. The release of cys-LT, TNF, CCL2 were 
measured by ELISA with the method described in chapter 2, section 2.3.10. 
4.3.5 Lipid raft isolation and western blot analysis  
Lipid rafts were isolated from BMMC following treatment with 10 mM MBCD 
(Sigma-Aldrich) for 30 min with the method described in chapter 3, section 3.3.6. 
Western blot analysis was performed with the method described in chapter 3, section 
3.3.8. 
4.3.6 Statistical analysis 
The differences on cell viability before and after MBCD treatment were determined 
using Student's t-test. Two-way analysis of variance (ANOVA) followed by the post-hoc 
Bonferroni test were used to evaluate the difference in mediator release between WT and 
fat-1 BMMC with and without MBCD treatment. Statistical significance was set at 
p<0.05.  Statistical analysis was performed in SPSS 11.5 statistical software package 
(IBM Corporation, Armonk, NY).   
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4.4 Results 
4.4.1 The effect of MBCD treatment on BMMC viability 
In both WT and fat-1 BMMC, there was no significant difference in viability 
between untreated cells and cells treated with 10 mM MBCD for 30 min (Fig. 4.1).  
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Figure 4.1 Cell viability of BMMC after MBCD treatment. WT and fat-1 BMMC 
viability were evaluated by XTT assay after 30 min 10 mM MBCD treatment and is 
compared to untreated control. Error bars represent standard error of the mean (SEM) 
(n=3). XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5- 
carboxanilide; WT: Wild type. 
 
 
 
 
 
 
 
 
WT fat-1
0.0
0.2
0.4
0.6
0.8
1.0
untreated
MBCD
Ab
so
rb
an
ce
172 
 
4.4.2 The effect of MBCD treatment on FcİRI-mediated BMMC degranulation  
Following 0%&'WUHDWPHQWWKHȕ-hex release level (% of total) was low (<20%, 
maximally) in both types of BMMC (Fig. 4.2A). Control WT and fat-1 BMMC that 
received no MBCD treatment had a  maximum of 41.6% and 33.3% ȕ-hex release 
respectively (Fig. 4.2B and C). In addition, there was no significant difference in ȕ-hex 
release between MBCD-treated WT and fat-1 BMMC in different concentrations of 
DNP-HSA (Fig. 4.2A). Without the activation by DNP-HSA, MBCD treatment alone 
caused significantly higher ȕ-hex release than untreated cells in both WT and fat-1 
BMMC (p=0.036 and p=0.041) (Fig. 4.2B and C). In response to 10, 100, 200, and 500 
ng/mL DNP-HSA stimulation, both MBCD-treated WT and fat-1 BMMC produced 
significantly less ȕ-hex compared to untreated controls (p<0.05) (Fig. 4.2B and C). 
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4.4.3 The effect of MBCD treatment on FcİRI-mediated cys-LT release by BMMC  
Similar to the degranulation results, the cys-LTs release level was very low (<70 
pg/mL, maximally) in IgE/DNP-HSA-stimulated WT and fat-1 BMMC after MBCD 
treatment (Fig. 4.3A). Without MBCD treatment, WT and fat-1 BMMC produced 
maximally 1612.6 and 1181.3 pg/mL cys-LTs respectively (Fig. 4.3B and C). There 
was no significant difference between WT and fat-1 BMMC in IgE/DNP-HSA-induced 
cys-LTs release after MBCD treatment (Fig. 4.3A). In response to 1, 10, 100, 200, and 
500 ng/mL DNP-HSA stimulation, both MBCD-treated WT and fat-1 BMMC 
produced significantly less cys-LTs compared to their untreated control (p<0.05) (Fig. 
4.3B and C). 
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4.4.4 The effect of MBCD treatment on FcİRI-mediated cytokine/chemokine 
production by BMMC  
IgE/DNP-HSA-induced TNF production by WT and fat-1 BMMC was very low 
(<15 pg/mL, maximally) following MBCD treatment, and no significance was found 
between WT and fat-1 BMMC in TNF production after MBCD treatment (Fig. 4.4A). 
Without MBCD treatment, WT and fat-1 BMMC produced a maximum of 982.8 and 
738.0 pg/mL TNF respectively (Fig. 4.4B and C). In response to 1, 10, 100, 200, and 
500 ng/mL DNP-HSA stimulation, both MBCD-treated WT and fat-1 BMMC 
produced significantly less TNF compared to their untreated control (p<0.005) (Fig. 
4.4B and C). 
Following MBCD treatment, the CCL2 production in response to IgE/DNP-HSA 
was less than 100 pg/mL at maximum, in both WT and fat-1 BMMC (Fig. 4.5A). 
Without MBCD treatment, WT and fat-1 BMMC produced maximally 1640.3 and 
1131.3 pg/mL CCl2 respectively (Fig. 4.5B and C). MBCD-treated fat-1 BMMC 
produced less CCl2 (51.5 pg/mL compared to 85.9 pg/mL, p=0.001) in response to 10 
ng/mL DNP-HSA compared to MBCD-treated WT BMMC (Fig. 4.5A). In response to 
1, 10, 100, 200, and 500 ng/mL DNP-HSA stimulation, both MBCD-treated WT and 
fat-1 BMMC produced significantly less CCL2 compared to their untreated controls 
(p<0.005) (Fig. 4.5B and C). 
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4.4.5 The effect of MBCD treatment on )Fİ5,DQG/\QORFDOL]DWLRQLQOLSLGUDIWVof 
BMMC 
Without MBCD treatment, the H[SUHVVLRQRI)Fİ5,LQOLSLGUDIWVof WT BMMC 
was higher (54.8 %, p=0.003) than in lipid rafts of fat-1 BMMC (Fig. 4.6A and B left). 
However, after MBCD treatment, the expression of )Fİ5,DQG/\QZHUHdramatically 
decreased in lipid rafts of WT and fat-1 BMMC compared to their untreated control 
(Fig. 4.6A). In addition, no significant difference in raft )Fİ5, H[SUHVVLRQ EHWZHHQ
MBCD-treated WT and fat-1 BMMC was found (Fig. 4.6B right).  
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4.5 Discussion 
In this study, both WT and fat-1 BMMC had an inhibited response to IgE/antigen 
following MBCD treatment. IgE/antigen-induced degranulation, lipid-derived mediator 
release and cytokine/chemokine production were all disrupted by MBCD pretreatment 
due to reduced )Fİ5,DQG/\QORFDOL]DWLRQLQUDIWV7KHGLIIHUHQFHLQPHGLDWRUUHOHDVH
DQG)Fİ5,UDIWH[SUHVVLRQEHWween WT and fat-1 BMMC detected in chapters 2 and 3 
disappeared after MBCD treatment, suggesting that cholesterol has a greater influence 
than long chain n-3 PUFAs on FcİRI localization in lipid rafts and FcİRI-mediated 
mediator release of mast cells. 
Lipid rafts are involved in the processes of endocytosis, exocytosis, receptor 
signaling, and pathogen entry and replication (Calder and Yaqoob, 2007; Hanzal-Bayer 
and Hancock, 2007; Zajchowski and Robbins, 2002). In mast cells, lipid rafts are 
UHTXLUHGIRU)Fİ5,HQGRF\WRVLVXELTXLWLQDWLRQDQGGHJUDGDWLRQLQO\VRVRPHV(Silveira et 
al., 2011). A lipid raft component, ganglioside derived from GD1b, is expressed by mast 
cells in all stages of maturation (Zuberbier et al., 1999), and is internalized together with 
)Fİ5, GXULQJ UHFHSWRU HQGRF\WRVLV (Mazucato et al., 2011). Lipid rafts are also 
associated with soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNAREs) which aggregates proteins required for exocytosis in mast cells (Puri and 
Roche, 2006)+RZHYHUOLSLGUDIWVDUHHVSHFLDOO\LPSRUWDQWIRU)Fİ5,-mediated signal 
transduction, which occurs at a sub-second scale, and contains collections of secondary 
messengers required for signaling initiation and propagation (Siraganian, 2003))Fİ5,
was found to co-localize with Lyn in lipid rafts (Wilson et al., 2000) which is anchored 
to the inner leaflet of the plasma membrane through myristate and palmitate chains 
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(Kovarova et al., 2001). Within the lipid raft, a direct interaction between Lyn and the 
)Fİ5,ȕFKDLQPD\H[LVW(Vonakis et al., 1997). Interestingly, the activity of Lyn in lipid 
rafts is much higher than outside of lipid rafts (Young et al., 2003), which suggests that 
OLSLGUDIWVPD\QRWEHHVVHQWLDOIRU)Fİ5,VLJQDOWUDQVGXFWLRQEXWQHFHVVDU\IRUDQRSWLPDO
response.  
Cholesterol is an essential raft component required for raft stabilization (Lingwood 
and Simons, 2010). Exogenous cholesterol was shown to activate CPII mouse mast cells 
by inducing activation of P38 and FosB following incorporation to rafts (Baumruker et 
al., 2003). As small polar molecules that possess hydrophobic pockets to capture 
cholestHURO ȕ-cyclodextrins can remove cholesterol in cells. Cholesterol depletion 
FDXVHGE\ȕ-cyclodextrins can be reversed by exogenous cholesterol treatment (Barman 
and Nayak, 2007). MBCD is relatively less-WR[LFDPRQJȕ-cyclodextrins (Kiss et al., 
2007), which was widely used to explore the role of lipid rafts in functions of various 
types of cells. It was reported that MBCD treatment disrupted PIP2 localization in rafts, 
suppressed RBL-2H3 cell degranulation and calcium influx induced by IgE/antigen 
(Yamashita et al., 2001) +RZHYHU WKH SKRVSKRU\ODWLRQ RI )Fİ5, VXEXQLWV DQG
phospholipase C-Ȗ (PLC-Ȗ) were not influenced (Yamashita et al., 2001). There were 
conflicting results from another study using the same type of cell, which showed that 
MBCD treatment does not significantly inhibit IgE/antigen induced degranulation, but 
instead enhances calcium ionophore-induced degranulation (Sheets et al., 1999). The 
SKRVSKRU\ODWLRQ RI )Fİ5, ZDV LQKLELWHG E\ MBCD treatment, and the interaction of 
)Fİ5,/\QDQGUDIWVZDVGLVUXSWHG(Sheets et al., 1999). RBL-2H3 cells were reported to 
H[SUHVV GLIIHUHQW OHYHO RI )Fİ5, LQ GLIIHUHQW FXOWXUH FRQGLWLRQV (Froese et al., 1982), 
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which may result in the difference between results described above. In 3ȕ-hydroxysterol 
ǻ-reductase (DHCR) deficient mast cells, whose membranes contain depleted 
cholesterol and accumulated cholesterol precursor 7-dehydrocholesterol (DHC), lipid 
raft stability was disrupted and the expression of Lyn in rafts was suppressed (Kovarova 
et al., 2006). However, hyper-degranulation was observed as a result of decreased 
phosphorylation of Csk-binding protein, which is dependent on Lyn and function as a 
negative regulator for degranulation-promoting Fyn activity (Kovarova et al., 2006). 
The current study showed that MBCD treatment inhibited leukotriene production in 
both WT and fat-1 BMMC. A similar effect was observed in RBL-2H3 cells (You et al., 
2007). After MBCD incubation, the leukotriene synthesis induced by calcium ionophore 
was diminished, which can increase the intracellular calcium level by facilitating the 
cross of calcium to cell membrane and entry to cells. This observation was reversed by 
cholesterol treatment (You et al., 2007). A critical molecule involved in leukotriene 
synthesis, 5-lipoxygenase activating protein (FLAP), was found to co-localize with a 
lipid raft marker, flotillin-1, suggesting the localization of FLAP in lipid rafts (You et al., 
2007). Thus, cholesterol depletion may directly down-regulate leukotriene production 
by disrupting FLAP function in rafts.  
The results of this study also demonstrated reduced cytokine/chemokine 
production in MBCD-treated mast cells, which was not reported in any other previous 
studies on mast cells. However, similar effects can be found in macrophages. MBCD 
treatment was seen to decrease TNF expression in both mRNA and protein levels in 
RAW264.7 murine macrophage cells stimulated with lipopolysaccharide (LPS) 
(Nishiyama et al., 2008).The result of this study also showed that the CCL2 production 
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after MBCD treatment is lower in fat-1 BMMC than WT, suggesting cholesterol and 
long chain n-3 PUFA together may result in more impaired mast cell activation than 
cholesterol alone. This study is the first report to show an inhibitory effect of MBCD 
treatment in )Fİ5,-mediated activation of primary WT and long chain n-3 
PUFA-enriched mast cells. In .RYDURYD¶s study (Kovarova et al., 2006), the mice were 
genetically modified to have depleted cholesterol together with accumulated 7-DHC, 
which might have an influence on cell function. 
)Fİ5,DQG/\QH[SUHVVLRQLQOLSLGUDIWVZDVGLVUXSWHGE\0%&'WUHDWPHQWLQERWK
WT and fat-1 BMMC, which might be responsible for the results shown in this study. 
Disruption of receptor expression in lipid rafts by cholesterol depletion is a common 
phenomenon (Simons and Toomre, 2000; Zidovetzki and Levitan, 2007). For instance, 
cholesterol is not only connected to the production of leukotrienes, but also involved in a 
FHOO¶VUHVSRQVHWRLTs. LTB4 receptor BLT-1 is reported to be expressed in lipid rafts 
together with flotillin-1 in human neutrophils (Sitrin et al., 2006). MBCD treatment 
disrupted BLT-1 raft expression and suppressed neutrophil activation induced by LTB4 
(Sitrin et al., 2006). However, the current study is the first one to report GLVUXSWHG)Fİ5,
expression in rafts of the primary mast cells by MBCD treatment. The result of this 
study also showed that )Fİ5,DQG/\QH[SUHVVLRQLQOLSLGUDIWVZDVequally reduced in 
WT and fat-1 BMMC by MBCD treatment, even though the fat-1 BMMC contain less 
)Fİ5, in lipid rafts than WT (Fig. 3.11), suggesting MBCD-caused defect on 
cholesterol may have stronger effect on protein localization in lipid rafts than long 
chain n-3 PUFA incorporation.  
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In summary, these results showed that MBCD pretreatment suppresses 
IgE/antigen-induced mast mediator release, and disrupt raft localization of )Fİ5,DQG
Lyn in both WT and fat-1 BMMC, suggesting a greater influence of cholesterol on 
lipid raft function than long chain n-3 PUFA. Both WT and long chain n-3 
PUFA-enriched mast cells require cholesterol for proper response to IgE/antigen. The 
importance RIOLSLGUDIWVLQ)Fİ5,-mediated mast cell mediator release is supported by 
this study.  
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GENERAL DISCUSSION, CONCLUSIONS, AND FUTURE 
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5.1 General discussion 
5.1.1 Lipid raft functions in immune responses 
As introduced in chapter 1, lipid rafts have been proposed to take part in innate and 
adaptive immune responses by sequestering lipids and proteins in macrophages, T cells 
and B cells (Simons and Toomre, 2000). This study supports the role of lipid rafts in the 
regulation of signal transduction in mast cells. Fc İ receptor I ()Fİ5,) can be found in 
the lipid rafts of resting mast cells and concentrates in rafts after cell activation. This 
supports the first and second model of lipid rafts in signal transduction, described in the 
chapter 1 (section 1.3.2), emphasizing the presence and quick partitioning of receptors to 
lipid rafts. Lipid rafts, with their concentrated )Fİ5, and Lyn, are important for 
)Fİ5,-mediated signal transduction which is extremely quick (Liu et al., 2013). The 
preformed mediators in granules of mast cells can be released within seconds after 
encountering an antigen. In the current study, long chain n-3 PUFAs were shown to 
inhibit immunoglobulin E (IgE)/antigen-induced release of mast cell mediators and 
FcİRI-mediated signal transduction by disrupting FcİRI localization in rafts of resting 
cells and FcİRI shuttling to rafts in activated cells, and expression of Lyn and linker of 
activated T cells (LAT) (chapter 2 and 3).  
5.1.2 Lipid raft functions in mast cells 
This study supports the important function of lipid rafts in )Fİ5,-mediated signal 
transduction and activation of mast cells. However, the results of the present study are 
not entirely consistent with some previous studies.The results of this study suggest that 
)Fİ5,can be found in lipid rafts in resting mast cells, which was not seen in a previous 
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study in which )Fİ5,was detected in lipid rafts of RBL-2H3 basophilic leukemia cells 
only after cross-linking (Field et al., 1997). RBL-2H3 cells, which are generated from 
basophilic leukemia, are not perfect analogies to mast cells (Passante et al., 2009). For 
example, RBL-2H3 cells do not respond well to lipopolysaccharide (LPS) because of the 
absence of cluster of differentiation (CD) 14 expression (Passante et al., 2009), which is 
present in both human and mouse mast cells (McCurdy et al., 2001; Welker et al., 2000). 
Although RBL-2H3 cells share some characteristics with mucosal mast cells and are 
easy to culture, conflicting results using this cell line are commonly seen in different 
laboratories, possibly because they are sensitive to different culture conditions (Froese et 
al., 1982) )RU LQVWDQFH )Fİ5, H[SUHVVLRQ in RBL-2H3 cells from four different 
laboratories cultured with the same protocol were reported to express different levels of 
)Fİ5,ZLWKLQFRQVLVWHQWPROHFXODUZHLJKWV(Froese et al., 1982).  
Another explanation for the difference between the results of the present study and 
Field¶s study is that the lipid raft isolation method is different. I modified a lipid raft 
isolation protocol published by Dr. D.A. Brown in 2002 (Brown, 2002), which has 
been used by many subsequent studies with or without minor modifications (Lopez et 
al., 2012). Field et al (Field et al., 1997) used 0.05% Triton X-100 to lyse the cells, and 
the sucrose gradient was set up as 80%, 60%, 40% , 30%, 20%, and 10%. While I used 
1% Triton X-100 with two additional protease inhibitors, leupeptin and pepstatin, to 
lyse the cells. Leupeptin and pepstatin may provide further protection for raft proteins 
from degradation, which is vital in the present study because mast cells are known to 
contain many types of proteases (Gilfillan and Tkaczyk, 2006). The sucrose gradient in 
the present study was set at 44%, 35% and 5%. Furthermore, SW41 rotor was used in 
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the present study for ultracentrifuge at 100,000 × g for 3 hours (hr), while Field et al 
used a SW60.1 rotor at 250,000 × g for 12-18 hr. In the present study, 30 minutes (min) 
methyl-ȕ-cyclodextrin (MBCD) treatment inhibited IgE/antigen-induced degranulation, 
lipid-derived mediator release and cytokine/chemokine production in both WT and 
fat-1 bone-marrow-derived mast cells (BMMC), confirming that cholesterol, an 
important lipid raft component, is HVVHQWLDOIRU)Fİ5,-mediated mediator release of mast 
cells.  
5.1.3 Fatty acids/lipid effects on mast cells 
The present study is the first to provide comprehensive evidence that n-3 
polyunsaturated fatty acids (PUFAs) have an effect on mast cell activation. In addition, 
)Fİ5,association with raftsEXWQRWH[SUHVVLRQRI)Fİ5,RQFHOOVXUIDFHDQGZKROHFHOO
lysates, is disrupted by n-3 PUFA incorporation, thus changing the property of the rafts. 
In addition, endogenously produced long chain n-3 PUFAs actually decreased Lyn and 
LAT whole cell expression in mast cells, which may be the result of binding of long 
chain n-3 PUFAs on free fatty acid receptors and peroxisome proliferator-activated 
receptors (Calder, 2013). 
Lipids other than n-3 PUFAs may also have modulating roles in mast cell function. 
In C2 cells, 8-day treatment of linoleic acid (18:2 n-6) enhanced tryptase activity in 
resting cells and amplified histamine release in response to mastoparan (Gueck et al., 
2004), a peptide toxin from wasp venom. Phospholipase D (PLD) is an enzyme that 
catalyzes the hydrolysis of a major membrane phospholipid, phosphatidylcholine, to 
phosphatidic acid and choline. Phospholipase D is believed to be an important player  in 
exocytosis and vesicle trafficking (Shen et al., 2001). Arachidonic acid (AA, n-6) was 
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reported to protect PLD activity in the presence of PLD inhibitors in C2 canine 
mastocytoma cells (Basiouni et al., 2013). AA treatment was also reported to increase 
AA levels in both raft and non-raft membrane regions of C2 mast cells (Basiouni et al., 
2012). After a 24 hr AA incubation, >50% of AA was shown to incorporate into 
phosphatidylcholine in membranes of human lung mast cells, and IgE/anti-IgE-induced 
histamine release was significantly higher than control (Peters et al., 1984).  
Another lipid type that has gained some interest in this field is cholesterol, as 
described in chapter 4. The results showed that MBCD treatment inhibited 
IgE/antigen-induced mediator release in both WT and fat-1 BMMC. Similar to the 
results of the present study, cholesterol depletion was shown to inhibit mast cell 
DFWLYDWLRQ E\ VXSSUHVVLQJ )Fİ5, SKRVSKRU\ODWLRQ DQG /\Q ORFDOL]DWLRQ LQ UDIWV
(Kovarova et al., 2006). In addition, exogenous cholesterol treatment lead to an 
increased cholesterol level in rafts, and induced degranulation and leukotriene 
production from CPII mouse mast cells by causing P38 kinase activation (Baumruker et 
al., 2003).  
5.1.4 Clinical meaning of this study for patients with mast cell-mediated disease 
This study showed that long chain n-3 PUFAs can modulate lipid raft function and 
inhibit mast cell activation mediated by FcİRI, which is the principle activating 
pathway of mast cells. In addition, lipid rafts are involved in a broad range of signaling 
pathways as described in chapter 1, section 1.3.2. Therefore, long chain n-3 PUFAs 
might be a valuable supplement for mast cell-mediated diseases, such as allergic asthma, 
urticaria, mastocytosis and atopic dermatitis.  
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N-3 PUFAs may also have a potential beneficial effect on cancer. In recent years, 
inflammation has started to be considered as a fundamental and universal event in cancer 
development (Grivennikov et al., 2010). Furthermore, the role of mast cells in cancer 
development is becoming recognized (Khazaie et al., 2011). Mast cells are found to 
accumulate around tumor sites in both human and rodent cancers, including breast, lung, 
liver and prostate cancer (Nonomura et al., 2007; Ranieri et al., 2009; Stoyanov et al., 
2012; Terada and Matsunaga, 2000). The roles of mast cells in cancer are thought to be 
multifaceted. An increased number of mast cells in peritumoral tissue in prostate cancer 
is associated with a bad prognosis, whereas increased numbers of mast cells in 
intratumoral tissue is associated with a good prognosis (Fleischmann et al., 2009; 
Johansson et al., 2010). There was also a study showing that mast cell numbers in 
intratumoral border zone are correlated with a bad prognosis of pancreatic ductal 
adenocarcinoma (Cai et al., 2011). However, mast cell numbers in the intratumoral 
center zone and the peritumoral zones were not associated with the prognosis of 
pancreatic cancer (Cai et al., 2011), suggesting that the role of mast cell in cancer 
might be dependent on the specific cancer types. The consumption of long chain n-3 
PUFAs has been associated with lower risk of breast cancer (Zheng et al., 2013). 
Because long chain n-3 PUFAs are food components with large applicable safe-dose 
ranges, they have some overwhelming merits to be used in disease treatment. First, they 
can be used for long term with almost no or negligible side effects, making them suitable 
for chronic conditions. Second, they may help reduce the use of medicines with 
well-documented undesirable side effects. For example, inhaled and oral corticosteroids 
are very effective long-term control medications for asthma, but the side effects of 
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corticosteroids can include growth inhibition, adrenal suppression, dermal thinning, 
hypertension, cataracts, and muscle weakness (Dahl, 2006). Chronic use of 
corticosteroids may also lead to immunologic attenuation (Walker and Edwards, 2013). 
Reduction in the corticosteroid dosage can contribute to an improvement in the quality 
of life in patients.    
5.1.5 n-3 PUFAs and lipid rafts in cells other than mast cells 
The importance of lipid rafts in modulating receptor signal transduction was 
observed in many types of cells besides mast cells, suggesting that their function is 
ubiquitously present in a broad range of cells (Simons and Toomre, 2000). 
Docosahexaenoic acid (DHA)  supplementation was reported to increase DHA levels in 
lipid rafts of T cells, thus decreasing IL-2 receptor and STAT5a/b expression in rafts (Li 
et al., 2005). In colonic epithelial cells, DHA was shown to change lipid raft composition 
and suppress activation of ERK1/2, STAT3, and mammalian target of 
rapamycin (mTOR) induced by epidermal growth factor (EGF) both in vivo and in vitro 
(Turk et al., 2012). A similar phenomenon was observed in human breast cancer cells, 
where eicosapentaenoic acid (EPA) and DHA inhibited proliferation and induced 
apoptosis of MDA-MB-231 human breast cancer cells by changing lipid composition of 
rafts and decreasing EGF receptor (EGFR) expression in rafts (Schley et al., 2007). In 
addition, fish oil and DHA have been reported to inhibit DNA binding activity 
of activator protein 1 (AP-1) and nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-kB) (Liu et al., 2001) which are master transcription factors modulating 
immune and inflammatory processes. In B cells, it was reported that cross-linking of 
raft-associated B cell receptors result in cell activation (Allsup et al., 2005). However, if 
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the antigen binds to B cell receptors that are not located in rafts in immature B cells, the 
cell will go into apoptosis or anergy (Sproul et al., 2000), indicating that lipid rafts have 
a great influence on the response and development of B cells.    
5.2 Conclusions  
In this study, endogenous and exogenous long chain n-3 PUFAs shifted the fatty 
acid profile in BMMC to a long chain n-3 PUFA-enriched composition with a decreased 
ratio of n-6 to n-3. Mast cell activation was suppressed by long chain n-3 PUFA 
inhibition of Lyn and LAT expression and t h e  disruption of )Fİ5,association with 
lipid rafts of both resting and activated cells, but not )Fİ5,expression on cell surfaces 
or in whole cells. Consistent with reduced degranulation, lipid-derived mediator and 
cytokine/chemokine production and release, )Fİ5,-mediated signal transduction was 
shown to be suppressed by long chain n-3 PUFAs. The IgE/antigen induced 
phosphorylation of three vital signaling molecules, Lyn, spleen tyrosine kinase (Syk) 
and LAT, was inhibited. These results support my hypothesis that long chain n-3 PUFAs 
LQKLELWPDVWFHOODFWLYDWLRQE\GLVUXSWLQJ)Fİ5,ORFDOL]DWLRQand shuttling to lipid rafts 
and expression of some signaling molecules. The inhibitory effect of long chain n-3 
PUFAs on mast cell activation requires cholesterol. Connections among long chain n-3 
PUFAs, lipid rafts, receptor signal transduction, and mast cell-associated diseases are 
indicated. 
5.3 Future directions 
There are several valuable research questions that can be explored based on the 
results of this project. First, in addition to influencing the expression of Lyn and LAT, 
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disrupting )Fİ5, ORFDOL]ation in lipid rafts, inhibiting subsequent signal transduction, 
suppressing phosphatidylinositol 4, 5-bisphosphate (PIP2) distribution in rafts is another 
possible mechanism that long chain n-3 PUFAs may disrupt mast cell activation. PIP2 is 
the precursor of the second messengers, inositol trisphosphate (IP3) and diacylglycerol 
(DAG), which induce protein kinase C (PKC) activation and calcium response. Inthe 
present study, long chain n-3 PUFAs were shown to alter lipid composition in lipid rafts 
or, in other words, raft property. A report has been published showing that lipid raft 
destabilization can inhibit PIP2 content in rafts (van Rheenen et al., 2005).  
Second, the current study raises the question as to how long chain n-3 PUFAs 
modulate Lyn and LAT in mast cells. PPARs and free fatty acid receptors, GPR40 and 
GPR120, are possible candidates. 
Third, the effects of long chain n-3 PUFAs and/or lipid rafts on signal transduction 
of other receptors in mast cells could be different than the mechanism described in this 
study. Mast cells express a broad range of cell surface receptors. The results of chapter 3 
have shown tKDW)Fİ5,LVDVVRFLDWHGZLWKOLSLGUDIWVERWKLQUHVWLQJDQGDFWLYDWHGPDVW
cells, and changes in lipid raft fatty acid profile influenced )Fİ5,-mediated signal 
transduction. However, N-methyl-D-aspartate (NMDA) receptor signaling pathway, 
which is also expressed on mast cells (Daeffler et al., 1999), was not altered by changes 
in lipid raft property (Nothdurfter et al., 2013). It is worthwhile to study the effect of long 
chain n-3 PUFAs on signaling pathways of other receptors in mast cells with different 
properties than )Fİ5,  
Fourth, the effect of DGLA (20:3 n-6), a n-6 PUFA acting as a precursor for 
anti-inflammatory 1-series prostaglandins, but not leukotrienes (Levin et al., 2002), is 
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another candidate that may have protective effects against mast cell activation. As a 
PUFA, it may also regulate membrane function. Furthermore, the 15-hydroxyl 
derivative from DGLA inhibits leukotriene synthesis from AA (Samuelsson, 1987). 
Long chain n-3 PUFAs also function in modulating membrane function and inhibiting 
eicosanoid production from AA. Thus, a synergistic effect on mast cell activation may 
exist between DGLA and long chain n-3 PUFAs.  
Fifth, based on in vitro results of this study, in vivo studies can be designed to look 
at the effects of long chain n-3 PUFAs on the whole body. To optimize the effects, it 
might be necessary to try different combinations of EPA, DHA and DGLA, which may 
result in an optimized formula for beneficial effects of PUFA supplementation.  
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